EP4255405A1 - Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes - Google Patents

Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes

Info

Publication number
EP4255405A1
EP4255405A1 EP21901328.1A EP21901328A EP4255405A1 EP 4255405 A1 EP4255405 A1 EP 4255405A1 EP 21901328 A EP21901328 A EP 21901328A EP 4255405 A1 EP4255405 A1 EP 4255405A1
Authority
EP
European Patent Office
Prior art keywords
cannabinoid
composition
compound
therapeutic compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21901328.1A
Other languages
German (de)
English (en)
Inventor
William KLEIDON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ojai Energetics PBC
Original Assignee
Ojai Energetics PBC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ojai Energetics PBC filed Critical Ojai Energetics PBC
Publication of EP4255405A1 publication Critical patent/EP4255405A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
    • C12C5/00—Other raw materials for the preparation of beer
    • C12C5/02—Additives for beer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • compositions suffer from drawbacks limiting their utility for administration to subjects. Many compositions are destroyed, broken down, or cleared by the liver, resulting in reduced delivery to the subject. Many therapeutic compositions also have low bioavailability and shelf life stability.
  • compositions having increased bioavailability, increased shelf stability, reduced first pass metabolism, and other beneficial properties are provided.
  • Therapeutic compositions of the present disclosure can be used to treat various diseases or conditions in subjects.
  • microencapsulation may involve generating a plurality of droplets in an emulsion.
  • the present disclosure provides a composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound, wherein the non-cannabinoid therapeutic compound is selected from the group consisting of Kyprolis, Epogen, Nplate, Vectibix, Blincyto, Corlanor, Evenity, Imlygic, Kanjinti, MVASI, Neupogen, Prolia, Repatha, Depakote, Gengraf, Kaletra, Leuplin, Mavyret, Oriahnn, Rinvoq, Survanta, Synthroid, ultane, venclexta, viekira, zemplar, Triumeq, Keytruda, Gardasil, Pneumovax, Ocrevus, Cyramza, doxorubicin, nano-inducing liposomal doxorubicin, a nano-inducing liposomal taxane, ketamine, a statin
  • At least one of i) the cannabinoid compound and ii) the non- cannabinoid therapeutic compound is encapsulated.
  • the non-cannabinoid therapeutic compound is doxorubicin.
  • the non-cannabinoid therapeutic compound is nano-inducing liposomal doxorubicin.
  • the non-cannabinoid therapeutic compound is the nano-inducing liposomal taxane.
  • the non-cannabinoid therapeutic compound is the ketamine.
  • the non-cannabinoid therapeutic compound is the statin.
  • the statin is atorvastatin.
  • the statin is fluvastatin.
  • the statin is lovastatin.
  • the non-cannabinoid therapeutic compound is the dextromethorphan.
  • the non-cannabinoid therapeutic compound is the non-steroidal antiinflammatory drug.
  • the non-steroidal anti-inflammatory drug is ibuprofen.
  • the non-steroidal anti-inflammatory drug is acetaminophen
  • the non-steroidal anti-inflammatory drug is naproxen.
  • the non-cannabinoid therapeutic compound is the benzodiazepine.
  • the benzodiazepine is diazepam.
  • the benzodiazepine is alprazolam.
  • the benzodiazepine is clonazepam.
  • the benzodiazepine is temazepam.
  • the cannabinoid compound is encapsulated.
  • the non-cannabinoid therapeutic compound is encapsulated.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in the same microcapsule of a plurality of microcapsules of the composition.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in different microcapsules of a plurality of microcapsules of the composition.
  • the composition is in a solid dosage form.
  • the solid dosage form comprises one or more members selected from the group consisting of a pill, tablet, powder, capsule, and granule.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are in the same solid dosage form.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are in different solid dosage forms.
  • the composition comprises a first unit dosage form comprising the cannabinoid compound and a second unit dosage form comprising the non-cannabinoid therapeutic compound, wherein the first unit dosage form and the second unit dosage form are for sequential or simultaneous administration to a subject in need thereof.
  • the composition is capable of synergistically yielding a greater degree of therapeutic efficacy in a subject in need thereof, as compared to either one of the cannabinoid compound and the non-cannabinoid therapeutic compound alone.
  • the present disclosure provides a kit comprising the composition of any one of the preceding embodiments, further comprising an instruction for administration of the composition to a subject in need thereof.
  • the present disclosure provides a method comprising administering the composition of any one of the preceding claims to a subject in need thereof.
  • the cannabinoid targets the endocannabinoid system.
  • the administration of the composition results in one or more effects from the group consisting of improved therapeutic window, decreased toxicity, decreased side effects, enhanced therapeutic effects, and enhancement of overall homeostasis through improvement in homeostasis in cells, organs, or entire body systems of the subject.
  • the present disclosure provides a composition comprising a cannabinoid compound and a non-cannabinoid therapeutic compound, wherein the non- cannabinoid therapeutic compound is selected from the group consisting of Enbrel, Neulasta, Prolia, XGEVA, Aranesp, Sensipar/Mimpara, Avsola, Otezla, Parsabiv, AndroGel, Creon, Duopa, Humira, Imbruvica, Niaspan, Orilissa, Skyrizi, Synagis, Trilipix, Advair, Tivicay, Breo/Relvar Ellipta, Ventolin, Lamictal, Avodart, Flovent, Augmentin, Rotarix, Shingrix, Januvia, Janumet, Isentress, Bridion, NuvaRing, Simponi, Zetia/Vytorin, Herceptin, Avastin, Rituxan, Perjeta, Xo
  • At least one of i) the cannabinoid compound and ii) the noncannabinoid therapeutic compound is encapsulated.
  • the non-cannabinoid therapeutic compound is the doxorubicin.
  • the non-cannabinoid therapeutic compound is the nano-inducing liposomal doxorubicin.
  • the non-cannabinoid therapeutic compound is the nano-inducing liposomal taxane.
  • the non-cannabinoid therapeutic compound is the ketamine.
  • the non-cannabinoid therapeutic compound is the statin.
  • statin is atorvastatin
  • the statin is fluvastatin.
  • the statin is lovastatin.
  • the non-cannabinoid therapeutic compound is the dextromethorphan.
  • the non-cannabinoid therapeutic compound is the non-steroidal ani- inflammatory drug.
  • the non-steroidal anti-inflammatory drug is ibuprofen.
  • the non-steroidal anti-inflammatory drug is acetaminophen.
  • the non-steroidal anti-inflammatory drug is naproxen.
  • the non-cannabinoid therapeutic compound is the benzodiazepine.
  • the benzodiazepine is diazepam.
  • the benzodiazepine is alprazolam.
  • the benzodiazepine is clonazepam.
  • the benzodiazepine is temazepam.
  • the cannabinoid compound is encapsulated.
  • the non-cannabinoid therapeutic compound is encapsulated.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in the same microcapsule of a plurality of microcapsules of the composition.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are encapsulated in different microcapsules of a plurality of microcapsules of the composition.
  • the composition is in a solid dosage form.
  • the solid dosage form comprises one or more members selected from the group consisting of a pill, tablet, powder, capsule, and granule.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are in the same solid dosage form.
  • the cannabinoid compound and the non-cannabinoid therapeutic compound are in different solid dosage forms.
  • the composition comprises a first unit dosage form comprising the cannabinoid compound and a second unit dosage form comprising the non-cannabinoid therapeutic compound, wherein the first unit dosage form and the second unit dosage form are for sequential or simultaneous administration to a subject in need thereof.
  • the composition is capable of synergistically yielding a greater degree of therapeutic efficacy in a subject in need thereof, as compared to either one of the cannabinoid compound and the non-cannabinoid therapeutic compound alone.
  • the present disclosure provides a kit comprising the composition of any one of the preceding embodiments, further comprising an instruction for administration of the composition to a subject in need thereof.
  • the present disclosure provides a method comprising administering a composition as in any one of the preceding embodiments to a subject in need thereof.
  • cannabinoid targets the endocannabinoid system.
  • the administration of the composition results in one or more effects from the group consisting of improved therapeutic window, decreased toxicity, decreased side effects, enhanced therapeutic effects, and enhancement of overall homeostasis through improvement in homeostasis in cells, organs, or entire body systems of the subject.
  • the present disclosure provides a method comprising administering to a subject in need thereof a composition comprising a cannabinoid compound and a non- cannabinoid therapeutic compound, wherein the non-cannabinoid therapeutic compound is selected from the group consisting of Kyprolis, Epogen, Nplate, Vectibix, Blincyto, Corlanor, Evenity, Imlygic, Kanjinti, MVASI, Neupogen, Prolia, Repatha, Depakote, Gengraf, Kaletra, Leuplin, Mavyret, Oriahnn, Rinvoq, Survanta, Synthroid, ultane, venclexta, viekira, zemplar, Triumeq, Keytruda, Gardasil, Pneumovax, Ocrevus, Cyramza, doxorubicin, nano-inducing liposomal doxorubicin, a nano-inducing lipo
  • the present disclosure provides a method comprising administering to a subject in need thereof a comprising a cannabinoid compound and a non-cannabinoid therapeutic compound, wherein the non-cannabinoid therapeutic compound is selected from the group consisting of Enbrel, Neulasta, Prolia, XGEVA, Aranesp, Sensipar/Mimpara, Aranesp, Avsola, Otezla, Parsabiv, AndroGel, Creon, Duopa, Humira, Imbruvica, Niaspan, Orilissa, Skyrizi, Synagis, Trilipix, Advair, Tivicay, Breo/Relvar Ellipta, Ventolin, Lamictal, Avodart, Flovent, Augmentin, Rotarix, Shingrix, Januvia, Janumet, Isentress, Bridion, NuvaRing, Simponi, Zetia/Vytorin, Hercept
  • FIG. 1A shows an example of a droplet generator.
  • FIG. IB shows another example of a droplet generator.
  • FIG. 1C shows an example of a microfluidic structure.
  • FIG. 2A shows an exemplary microscope image of an unprocessed composition of quillaja extract, hemp oil, and water at 400x magnification
  • FIG. 2B shows an exemplary microscope image of an unprocessed composition of quillaja extract, hemp oil, and water at lOOOx magnification
  • FIG. 3A shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, and water at 400x magnification
  • FIG. 3B shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, and water at 400x magnification
  • FIG. 3C shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, and water at lOOOx magnification
  • FIG. 3D shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, and water at lOOOx magnification
  • FIG. 4A shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, water, and sodium alginate at lOOOx magnification
  • FIG. 4B shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, water, and sodium alginate at lOOOx magnification
  • FIG. 4C shows an exemplary microscope image of a microfluidic processed composition of quillaja extract, hemp oil, water, and sodium alginate at lOOOx magnification;
  • FIGs. 5A-5D illustrate example tablets comprising the therapeutic compositions as disclosed herein;
  • FIGs. 6A-6D illustrate example pills comprising the therapeutic compositions as disclosed herein.
  • subject or “individual,” as used herein, generally refers to a vertebrate, such as a mammal.
  • a subject may be a patient.
  • Mammals can include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets.
  • Tissues, cells, and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
  • treatment generally refers to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit.
  • a therapeutic benefit can include a prophylactic benefit.
  • a treatment can comprise administering a composition (e.g., a therapeutic composition) disclosed herein.
  • therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment.
  • a composition can be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.
  • remission of the condition generally refers to a decrease in the effects or expression of an ailment, disease, condition, or medical problem or condition.
  • Remission of the subject may refer to remission of one or more conditions of the subject.
  • Remission of the condition may refer to mitigation of negative characteristics of the subject or the condition.
  • the term “effective amount” or “therapeutically effective amount” generally refers to the quantity of a composition as disclosed herein, that is sufficient to result in a desired activity upon administration to a subject in need thereof.
  • the term “therapeutically effective” can refer to that quantity of a composition that is sufficient to delay the manifestation, arrest the progression, relieve or alleviate at least one symptom of a disorder treated by the compositions or methods as disclosed herein.
  • the present disclosure provides therapeutic compositions comprising a plurality of different therapeutic drugs or compounds, and methods for the manufacture, delivery, and use of such compositions.
  • Combination of a plurality of different therapeutic drugs i.e., co-therapy
  • can synergistically yield a greater degree of efficacy e.g., a therapeutic efficacy in a subject in need thereof
  • Combination of a plurality of different therapeutic drugs e.g., into a single composition
  • the composition can comprise a first therapeutic compound (e.g., a cannabinoid compound) and a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound) that is different than the first therapeutic compound.
  • the composition can be in the form of a liquid, solid (e.g., pill, tablet, powder, capsule, granule, etc.), semi-solid (e.g., gel), or mixtures thereof.
  • the composition can comprise a first composition comprising a first therapeutic compound (e.g., a cannabinoid compound) and second composition comprising a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound).
  • a first therapeutic compound e.g., a cannabinoid compound
  • second composition comprising a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound).
  • the first composition and the second composition can be in the same unit dose (e.g., the same unit dosage form).
  • the first composition and the second composition can be in different unit doses (e.g., in different unit dosage forms).
  • the composition can be a solid composition (e.g., pill, tablet, powder, capsule, granule, etc.).
  • the solid composition can comprise a plurality of first therapeutic compounds (e.g., cannabinoid compounds) and a plurality of second therapeutic compounds (e.g., non-cannabinoid therapeutic compounds).
  • the plurality of first therapeutic compounds and the plurality of second therapeutic compounds can be mixed (e.g., homogenous mixture, non-homogeneous or heterogeneous mixture) within the solid composition.
  • the plurality of first therapeutic compounds and the plurality of second therapeutic compounds may not be mixed.
  • the plurality of first therapeutic compounds and the plurality of second therapeutic compounds may be in different portions of the solid composition.
  • one of the plurality of first therapeutic compounds and the plurality of second therapeutic compounds can be in a core of the solid composition and (2) the other of the plurality of first therapeutic compounds and the plurality of second therapeutic compounds can be in an outer layer (e.g., shell) of the core of the solid composition.
  • the solid composition can comprise a plurality of layers, and (1) one of the plurality of first therapeutic compounds and the plurality of second therapeutic compounds can be in a first layer of the plurality of layers while (2) the other of the plurality of first therapeutic compounds and the plurality of second therapeutic compounds can be in a second layer of the plurality of layers.
  • the first layer and the second layer can be adjacent to each other.
  • the first layer and the second layer can be separated by at least a third and different layer of the plurality of layers.
  • Different configurations of the plurality of first therapeutic compounds and the plurality of second therapeutic compounds within the solid composition can provide benefits such as, for example, shelf stability, improved bioavailability, reduced first-pass metabolism, and extended or modified release profiles (e.g., a first release profile of a first drug and a second release profile of a second drug that is different than the first release profile).
  • benefits such as, for example, shelf stability, improved bioavailability, reduced first-pass metabolism, and extended or modified release profiles (e.g., a first release profile of a first drug and a second release profile of a second drug that is different than the first release profile).
  • the present disclosure provides for encapsulation of therapeutic compositions as disclosed herein, and methods for the manufacture, delivery, and use of such compositions. At least a portion of the therapeutic compositions can be encapsulated, including in microcapsules. Microencapsulation can provide benefits such as shelf stability, improved bioavailability, reduced first-pass metabolism, and extended or modified release profiles (e.g., a first release profile of a first drug and a second release profile of a second drug that is different than the first release profile). Microencapsulation may involve generating a plurality of droplets in an emulsion.
  • Microencapsulation can increase solubility of the therapeutic compositions in water (e.g., solubility of oil-based therapeutic compositions), such as to ease delivery and/or administration of the therapeutic compositions to a subject.
  • the therapeutic compositions of the present disclosure can comprise cannabinoids, terpenes, essential oils, and other desirable compounds (e.g., non-cannabinoid therapeutic compounds).
  • the present disclosure provides a composition comprising a plurality of microcapsules, wherein an individual microcapsule of the plurality comprises one or more therapeutic compositions present in an amount of at least about one microgram.
  • an individual microcapsule of the plurality of microcapsules can comprise a plurality of different therapeutic compounds (e.g., a cannabinoid compound and a non-cannabinoid therapeutic compound).
  • a first individual microcapsule of the plurality of microcapsules can comprise a first therapeutic compound (e.g., a cannabinoid compound) and a second individual microcapsule of the plurality of microcapsules can comprise a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound).
  • an individual microcapsule of the plurality of microcapsules of the composition can comprise a cannabinoid compound (i.e., encapsulated cannabinoid compound) and the composition can further comprise a different therapeutic compound (e.g., a noncannabinoid therapeutic compound) that is not encapsulated.
  • an individual microcapsule of the plurality of microcapsules of the composition can comprise a noncannabinoid therapeutic compound (i.e., encapsulated non-cannabinoid therapeutic compound) and the composition can further comprise a non-encapsulated cannabinoid compound.
  • an individual microcapsule of the plurality of microcapsules can comprise (i) a first therapeutic compound (e.g., a cannabinoid compound) that is encapsulated and (ii) a second therapeutic compound (e.g., a non-cannabinoid therapeutic compound) that is disposed on the surface (e.g., outer surface, inner surface) of the individual microcapsule.
  • the individual microcapsule can comprise a plurality of amphiphilic molecules and the second therapeutic compound can be coupled to an amphiphilic molecule of the plurality of amphiphilic molecules (e.g., coupled to a hydrophilic portion of the amphiphilic molecule or a hydrophobic portion of the amphiphilic molecule).
  • the second therapeutic compound can be coupled to an outer surface of the individual microcapsule.
  • an individual microcapsule of the plurality of microcapsules can comprise a non-cannabinoid therapeutic compound as an emulsifier.
  • the non-cannabinoid therapeutic compound can be an amphiphilic molecule.
  • a plurality of such non-cannabinoid therapeutic compound can be used to form the plurality of microcapsules to encapsulate one or more cannabinoid compounds.
  • a non-cannabinoid therapeutic compound as disclosed herein may comprise a non-terpene compound.
  • Non-limiting examples of a non-cannabinoid therapeutic compound can comprise KYPROLIS (or carfilzomib) (e.g., for multiple myeloma), EPOGEN (or epoetin alfa) (e.g., for anemia), Nplate (or Romiplostim) (e.g., for Immune Thromboytopenia), Vectibix (or Panitumumab) (e.g., for Colorectal Cancer), Blincyto (or Blinatumomab) (e.g., for Cancer, such as acute lymphocytic leukemia (ALL)), Corlanor (or Ivabradine) (e.g., heart conditions, such as heart failure), Evenity (or Romosozumab-aqqg) (e.g., for osteoporosis, e.g., in postmenopausal women), Imlygic (or talim
  • Non-limiting examples of a non-cannabinoid therapeutic compound can comprise Enbrel (or Etanercept) (e.g., for rheumatoid arthritis), Neulasta (or Filgrastim) (e.g., for chemotherapy), Prolia (or Denosumab) (e.g., for bone cancer, such as osteosarcoma), XGEVA (or Denosumab) (e.g., for bone cancer, such as osteosarcoma), Aranesp (or Darbepoetin alfa) (e.g., for chemotherapy), Sensipar/Mimpara (or Cinacalcet) (e.g., for renal disease), Aranesp (or Darbepoetin alfa) (e.g., for anemia), Avsola (or infliximab-axxq) (e.g., for arthritis), Otezla (or Apremilast) (
  • non-cannabinoid therapeutic compound can comprise AndroGel (or testosterone gel) (e.g., for boosting testosterone), Creon (or pancrelipase) (e.g., for cystic fibrosis), Duopa or (carbidopa/levodopa) (e.g., for Parkinson's disease), Humira (or Adalimumab) (e.g., for Crohn's disease, Plaque Psoriasis, Rheumatoid arthritis), Imbruvica (Ibrutinib) (e.g., for Chronic Lymphocytic Leukemia), Niaspan (or Niacin) (e.g., for Cholesterol Treatment), Orilissa (or elagolix) (e.g., for pain associated with endometriosis), Skyrizi (or risankizumab-rzaa) (e.g., for pain associated with endometriosis), Skyrizi (or
  • non-cannabinoid therapeutic compound can comprise Advair (or Fluticasone propionate / Salmeterol) (e.g., for treating asthma and chronic obstructive pulmonary disease (COPD)), Tivicay (or Dolutegravir) (e.g., for antiretroviral threapty, e.g., HIV therapy), Breo/Relvar Ellipta (or fluticasone furoate and vilanterol) (e.g., for treating chronic obstructive pulmonary disease (COPD)), Ventolin (or Albuterol) (e.g., to prevent and/or treat wheezing and shortness of breath caused by breathing problems (e.g., asthma, chronic obstructive pulmonary disease)), Lamictal (or Lamotrigine) (e.g., to prevent and/or control seizures, mood swings of bipolar disorder in adults, etc.), Avodart (or Fluticasone propionate / Salmeterol) (e.g.,
  • non-cannabinoid therapeutic compound can comprise Advair (or Fluticasone propionate / Salmeterol) (e.g., for treating asthma and chronic obstructive pulmonary disease (COPD)), Tivicay (or Dolutegravir) (e.g., for antiretroviral threapty, e.g., HIV therapy), Breo/Relvar Ellipta (or fluticasone furoate and vilanterol) (e.g., for treating chronic obstructive pulmonary disease (COPD)), Ventolin (or Albuterol) (e.g., to prevent and/or treat wheezing and shortness of breath caused by breathing problems (e.g., asthma, chronic obstructive pulmonary disease)), Lamictal (or Lamotrigine) (e.g., to prevent and/or control seizures, mood swings of bipolar disorder in adults, etc.), Avodart (or Fluticasone propionate / Salmeterol) (e.g.,
  • non-cannabinoid therapeutic compound can comprise Depakote (or divalproex sodium) (e.g., for bipolar disorder), Gengraf (or Cyclosporine) (e.g., for preventing or reducing organ rejection in a subject who has received a tissue transplant, such as a liver, kidney, or heart transplant), Kaletra (or lopinavir/ritonavir) (e.g., for HIV), Leuplin (or leuprolide hormone) (e.g., for prostate cancer), Mavyret (or glecaprevir/pibrentasvir) (e.g., for Hepatitis C), Oriahnn (or an estrogen and progestin combination) (e.g., for menstrual bleeding related to uterine fibroids in women before menopause), Rinvoq (or upadacitinib) (e.g., for rheumatoid
  • non-cannabinoid therapeutic compound can comprise Triumeq (or a combination of abacavir, dolutegravir, and lamivudine) (e.g., for HIV).
  • non-cannabinoid therapeutic compound can comprise Januvia (or Sitagliptin) (e.g., for treatment of type 2 diabetes), Janumet (or Sitagliptin / Metformin) (e.g., for Diabetes, Obesity), Isentress (or Raltegravir) (e.g., for HIV/AIDS), Bridion (or Sugammadex) (e.g., for Anaestheis Reversal), active compounds in NuvaRing (or etonogestrel/ethinyl estradiol) (e.g., for Contraception), Simponi (or Golimumab) (e.g., for Rheumatoid arthritis), and Zetia/Vytorin (or Ezetimibe/Simvastatin) (e.g., to treat the symptoms of high cholesterol and to reduce cholesterol).
  • Januvia or Sitagliptin
  • Metformin e.g., for Diabetes, Obesity
  • Non-cannabinoid therapeutic compound can comprise Keytruda (or Pembrolizumab) (e.g., for non-small-cell lung cancer (NSCLC), melanoma, classical Hodgkin Lymphoma (cHL), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), gastric orgastroesophageal junction adenocarcinoma, and microsatellite instability-high (MSI-H) or mismatch repair deficient cancer), Gardasil (or Human Papillomavirus (HPV) Vaccine) (e.g., for HPV), and Pneumovax (or Pneumococcal Vaccination) (e.g., for Pneumococcal disease).
  • NSCLC non-small-cell lung cancer
  • cHL classical Hodgkin Lymphoma
  • HNSCC head and neck squamous cell carcinoma
  • MSI-H microsatellite instability-high
  • Gardasil
  • non-cannabinoid therapeutic compound can comprise Ocrevus (or ocrelizumab) (e.g., for Relapsing & Remitting MS (PRMS)).
  • Ocrevus or ocrelizumab
  • PRMS Relapsing & Remitting MS
  • Non-cannabinoid therapeutic compound can comprise Herceptin (or Trastuzumab) (e.g., for cancer, such as breast cancer), Avastin (or Bevacizumab) (e.g., for advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, relapsed glioblastoma), Rituxan (or Rituximab) (e.g., for blood cancer, rheumatoid arthritis, vasculitis), Perjeta (or Pertuzumab) (e.g., for Breast Cancer Medicine), Xolair (or Omalizumab) (e.g., Asthma), Actemra (or Tocilizumab) (e.g., for Rheumatoid Arthritis), Lucentis (or Ranibizumab) (e.g., Macular Degeneration), Activase/ T
  • Herceptin or Trastuzumab
  • Avastin or Be
  • non-cannabinoid therapeutic compound can comprise Cyramza (or Ramucirumab) (e.g., for cancer, such as stomach cancer).
  • Non-cannabinoid therapeutic compound can comprise Lantus (or Insulin glargine) (e.g., for Diabetes), Aubagio (or teriflunomide) (e.g., for Relapsing Remitting MS (RRMS)), Lovenox (or Enoxaparin sodium) (e.g., for thrombosis), Plavix (or Clopidogrel) (e.g., for Heart Attack, Stroke), Myozyme (or Alglucosidase alfa) (e.g., for Pompe Disease), Toujeo (or Insulin glargine) (e.g., for Diabetes), Dupixent (or Dupilumab) (e.g., Eczema, Dermatitis), and Fabrazyme (or agalsidase beta) (e.g., for Fabry disease).
  • Lantus or Insulin glargine
  • Aubagio or teriflunomide
  • Lovenox or Enoxapar
  • non-cannabinoid therapeutic compound can comprise Trulicity (or Dulaglutide) (e.g., for Diabetes), Humalog (or Insulin lispro) (e.g., for Diabetes), Alimta (or Pemetrexed) (e.g., for Cancer), Cialis (or Tadalafil) (e.g., for Erectile Dysfunction), Forteo (or Teriparatide) (e.g., for Osteoporosis), Humulin (or recombinant human insulin) (e.g., for Diabetes), Taltz (or Ixekizumab) (e.g., for Psoriasis), Basaglar (or Insulin glargine) (e.g., for Diabetes), and Cymbalta (or Duloxetine) (e.g., for Anxiety, Depression).
  • Trulicity or Dulaglutide
  • Humalog or Insulin lispro
  • Alimta or Pemetrexe
  • non-cannabinoid therapeutic compound can comprise Xarelto (or Rivaroxaban) (e.g., for Atrial Fibrillation), Eylea (or Aflibercept) (e.g., for Macular Degeneration), active ingredient of Mirena (or levonorgestrel) (e.g., for Contraception), Kogenate (or recombinant antihemophilic factor) (e.g., for Hemophilia), Nexavar (or Sorafenib) (e.g., for cancer), Yasmin (or drospirenone and ethinyl estradiol) (e.g., for contraception), Precose (or Acarbose) (e.g., for Diabetes), Adalat (or Nifedipine) (e.g., for Hypertension), Aspirin Cardio (or aspirin or acetylsalicylic acid
  • non-cannabinoid therapeutic compound (with indicated therapeutic applications) as disclosed herein can comprise one or more benzodiazepines from Table 2.
  • Non-cannabinoid therapeutic compound can comprise Tagrisso (or Osimertinib) (e.g., for lung cancer), Symbicort (or Budesonide / Formotero) (e.g., for asthma), Brilinta (or Ticagrelor) (e.g., for antiplatelet), Farxiga (or Dapagliflozin) (e.g., for type 2 diabetes), Nexium (or Esomeprazole) (e.g., acid reflux), Imfinzi (or Durvalumab) (e.g., for bladder cancer), Pulmicort (or Budesonide) (e.g., for asthma), Crestor (or Rosuvastatin) (e.g., for cholesterol), Lynparza (or Olaparib) (e.g., for fallopian tube cancer), and Faslodex (or Fulvestrant) (e.g., for Tagrisso (or Osimertinib) (e.g.
  • non-cannabinoid therapeutic compound as disclosed herein can comprise one or more opioid or opioid-mimetic from Table 3. TABLE 3.
  • Non-cannabinoid therapeutic compound can comprise Eliquis (or Apixaban) (e.g., for deep vein thrombosis and pulmonary embolism), Opdivo (or Nivolumab) (e.g., for melanoma, lung cancer, renal cancer), Spry cel (or Dasatinib) (e.g., for leukemia), Orencia SC (or abatacept) (e.g., for rheumatoid arthritis), Yervoy (or Ipilimumab) (e.g., for oncology), Orencia (or Abatacept) (e.g., for rheumatoid arthritis), Revlimid (or Lenalidomide) (e.g., for hepatitis B), Baraclude (or Entecavir) (e.g., for HIV/AIDS), Empliciti (or Elotuzumab)
  • Eliquis or Apixaban
  • Opdivo or Nivolumab
  • non-cannabinoid therapeutic compound as disclosed herein can comprise one or more drugs from Table 4.
  • non-cannabinoid therapeutic compound can comprise Stelara (or Ustekinumab) (e.g., for psoriasis), Remicade (or Infliximab) (e.g., for rheumatoid arthritis), Zytiga (or Abiraterone acetate) (e.g., for prostate cancer), Xarelto (or Rivaroxaban) (e.g., for deep vein thrombosis, pulmonary embolism), Invega Sustenna (or Paliperidone) (e.g., for schizophrenia), Simponi (or Golimumab) (e.g., for rheumatoid arthritis), Darzalex (or daratumumab) (e.g., for Multiple myeloma), Prezista (or Darunavir) (e.g., for HIV/AIDS), Imbruvica (
  • non-cannabinoid therapeutic compound as disclosed herein can comprise one or more generic drugs from Table 5.
  • Non-cannabinoid therapeutic compound can comprise Prevnar 13 (or Pneumococcal 13-valent Conjugate Vaccine) (e.g., for pneumococcal vaccine), Lyrica (or Pregabalin) (e.g., for epilepsy, neuropathy), Ibrance (Palbociclib) (e.g., for cancer), Enbrel (or Etanercept) (e.g., for rheumatoid arthritis), Lipitor (or Atorvastatin) (e.g., for cholesterol), Xeljanz (or Tofacitinib) (e.g., for arthritis), Chantix (or Varenicline) (e.g., for smoking cessation), Sutent (or Sunitinib) (e.g., for cancer), Norvasc (or Amlodipine) (e.g., for hypertension), and Premarin (or conjugate Vaccine) (e.g., for pneumococcal vaccine), Ly
  • Non-cannabinoid therapeutic compound can comprise Gilenya (or Fingolimod) (e.g., for autoimmune disease), Cosentyx (or secukinumab) (e.g., for Psoriasis, ankylosing spondylitis and psoriatic arthritis), Lucentis (or Ranibizumab) (e.g., for age-related macular degeneration), Tasigna (or Nilotinib) (e.g., for chronic myeloid leukemia), Sandostatin (or Octreotide) (e.g., for acromegaly), Gleevec (or Imatinib) (e.g., for Leukaemia, chronic myeloid (CML)), Afinitor (or Everolimus) (e.g., for oncology), Galvus (or Vildagliptin) (e.g., for diabetes), Prom
  • non-cannabinoid therapeutic compound as disclosed herein can comprise one or more cardiac medications from Table 7.
  • Non-cannabinoid therapeutic compound can comprise Entyvio (or Vedolizumab) (e.g., for ulcerative colitis, Crohn’s disease), Velcade (Bortezomib) (e.g., for multiple myeloma), Leuprorelin (or leuprolide) (e.g., for prostate cancer, breast cancer, endometriosis), Azilva (or azilsartan medoxomil) (e.g., for hypertension), Dexilant (or Dexlansoprazole) (e.g., for acid reflux), and Ninlaro (or Ixazomib) (e.g., for multiple myeloma).
  • Entyvio or Vedolizumab
  • Velcade Velcade
  • Leuprorelin or leuprolide
  • Azilva or azilsartan medoxomil
  • Dexilant or Dexlansoprazole
  • Ninlaro or Ixazom
  • non-cannabinoid therapeutic compound as disclosed herein can comprise one or more gastrointestinal agents from Table 8.
  • Non-cannabinoid therapeutic compound can comprise Genvoya (or a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) (e.g., for HIV treatment), Truvada (or Emtricitabine / Tenofovir) (e.g., for HIV treatment), Epclusa (or Sofosbuvir / Velpatasvir) (e.g., for Pre-exposure prophylaxis (PrEP)), Odefsey (or a combination of emtricitabine, rilpivirine, and tenofovir alafenamide) (e.g., for Hepatitis C treatment), Descovy (or Emtricitabine / Tenofovir) (e.g., for Liver cirrhosis), Harvoni (or ledipasvir/sofosbuvir)
  • Genvoya or a combination of elvitegravir, cobicist
  • Non-cannabinoid therapeutic compound can comprise Copaxone (or Glatiramer acetate) (e.g., for Relapsing-Remitting MS), Bendeka (or Bendamustine) (e.g., for Leukaemia, chronic lymphocytic Non-Hodgkin lymphoma), Methylphenidate Hydrochloride (e.g., for Attention deficit disorder/hyperactivity (ADD/ ADHD)), ProAir HFA (or Albuterol) (e.g., for Asthma), Austedo (or deutetrabenazine) (e.g., for Huntington’s disease, Tardive dyskinesia), Methylphenidate Hydrochloride (e.g., for Attention deficit disorder/hyperactivity
  • Copaxone or Glatiramer acetate
  • Bendeka or Bendamustine
  • Methylphenidate Hydrochloride e.g., for Attention deficit disorder/hyperactivity (ADD/ ADHD)
  • ADD/ ADHD QVAR RediHaler
  • QVAR RediHaler or beclomethasone - dipropionate HFA
  • Cubicin or Daptomycin
  • Metoprolol Succinate e.g., for Hypertension
  • Sildenafil Citrate e.g., for Erectile dysfunction
  • non-cannabinoid therapeutic compound (with indicated therapeutic applications) as disclosed herein can comprise one or more over the counter (OTC) health products from Table 10.
  • OTC over the counter
  • a non-cannabinoid therapeutic compound (with indicated therapeutic applications) as disclosed herein can comprise Hypochlorous acid (HOCL) (e.g., for blepharitis).
  • HOCL Hypochlorous acid
  • Non-limiting examples of conditions of diseases that can be ameliorated or treated with the non-cannabinoid therapeutic compound as disclosed herein can include rheumatoid arthritis, various cancers or tumors (e.g., breast cancer, bone cancer (such as osteosarcoma), colorectal cancer, lung cancer, kidney cancer, cervical cancer, ovarian cancer, relapsed glioblastoma, blood cancer, fallopian tube cancer, renal cancer, prostate cancer), renal disease, anemia, arthritis, severe plaque psoriasis, secondary hyperparathyroidism, testosterone deficiency, cystic fibrosis, Parkinson's disease, Crohn's disease, Plaque Psoriasis, Chronic Lymphocytic Leukemia, Cholesterol conditions (e.g., high cholesterol), pain associated with endometriosis, Plaque Psoriasis, viral infections (e.g., respiratory syncytial virus (RSV), DIV/AIDS), asthma, chronic obstructive pulmonary infections (e
  • Non-limiting examples of conditions of diseases that can be ameliorated or treated with the non-cannabinoid therapeutic compound as disclosed herein can include central nervous system (CNS) disease, such as addiction, arachnoid cyst, attention deficit/hyperactivity disorder (ADHS), autism, bipolar disorder, catalepsy, depression, encephalitis, epilepsy/seizures, infection, Locked-in syndrome, meningitis, migraine, multiple sclerosis, myelopathy, neurodegenerative disorders such as Alzheimer’s, Huntington’s, or Parkinson’s, etc.
  • CNS central nervous system
  • ADHS attention deficit/hyperactivity disorder
  • autism bipolar disorder
  • catalepsy depression
  • encephalitis epilepsy/seizures
  • infection Locked-in syndrome
  • meningitis migraine
  • multiple sclerosis multiple sclerosis
  • myelopathy neurodegenerative disorders
  • neurodegenerative disorders such as Alzheimer’s, Huntington’s, or Parkinson’s, etc.
  • the non-cannabinoid therapeutic compound as disclosed herein can be used as chemotherapeutic agent, anesthesia reversal agent, contraception agent, antiplatelet agent, post-tissue transplant medication (e.g., kidney transplant), or vaccine.
  • a composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound may be administered to a subject.
  • the subject may have or be suspected of having a condition (e.g., cancer).
  • the condition of the subject may be cancer of the breast, lung, stomach, ovary, or other organ or tissue.
  • the non-cannabinoid therapeutic compound may comprise or be doxorubicin.
  • the subject may be characterized by at least a partial remission of the condition.
  • a composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound comprising doxorubicin
  • the subject may be characterized by at least partial mitigation or remission of the cancer.
  • the composition comprising a cannabinoid and doxorubicin may mitigate the negative side effects of the doxorubicin in the subject.
  • the co- therapeutic composition comprising a cannabinoid and doxorubicin may mitigate cardiomyopathy during treatment of cancer by activating, binding, or otherwise interacting with endocannabinoid receptors in the heart.
  • the co-therapeutic composition may mitigate cardiomyopathy during treatment of cancer via mitochondrial pathways.
  • Administration of the composition comprising a cannabinoid in addition to a non- cannabinoid therapeutic compounds, such as doxorubicin, may result in an improved patient outcome compared to administration either the cannabinoid or non-cannabinoid therapeutic compound individually.
  • doxorubicin may salt, stereoisomer, or prodrug thereof.
  • a co-therapeutic composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound may be administered to a subject.
  • the subject may have or be suspected of having a condition, which treatment of the condition may comprise administration of the non-cannabinoid therapeutic compound (e.g., ketamine).
  • treatment of the condition by administering the co-therapeutic composition of the present disclosure may improve the treatment of the condition.
  • the non-cannabinoid therapeutic compound may comprise or be ketamine.
  • the subject may be characterized by at least a partial remission of the condition.
  • the subject subsequent to the administration of the composition comprising the cannabinoid and the non-cannabinoid therapeutic, the subject may be characterized by a least a partial reduction of negative side-effects as compared to administration of the non-cannabinoid therapeutic compound individually.
  • the subject subsequent to administration of a composition comprising a cannabinoid and ketamine, the subject may be characterized by one or more of diminished motor disturbance, antidepressant effects, and support of fear extinction in neural networks.
  • ketamine may salt, stereoisomer, or prodrug thereof.
  • a co-therapeutic composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound may be administered to a subject.
  • the subject may have or be suspected of having a condition (e.g. high cholesterol).
  • the condition may be a condition that is treated through administration of a statin.
  • the non-cannabinoid therapeutic compound may comprise or be a statin (e.g., atorvastatin, Fluvastatin, pravastatin, rosuvastatin, simvastatin).
  • the subject may be characterized by at least a partial remission of the condition. Subsequent to administration, the subject may be characterized by improved (e.g., decreased) cholesterol levels and/or neuroprotective effects from the administration of the co- therapeutic composition.
  • a cannabinoid and a non-cannabinoid therapeutic compound e.g., a statin
  • the subject may be characterized by improved (e.g., decreased) cholesterol levels and/or neuroprotective effects from the administration of the co- therapeutic composition.
  • atorvastatin may salt, stereoisomer, or prodrug thereof.
  • fluvastatin may salt, stereoisomer, or prodrug thereof.
  • lovastatin may salt, stereoisomer, or prodrug thereof.
  • a co-therapeutic composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound may be administered to a subject.
  • the subject may have or be suspected of having a condition, which treatment of the condition may comprise administration of the non-cannabinoid therapeutic compound.
  • the treatment of the condition may be improved by administration of the co-therapeutic compound comprising a cannabinoid and the non-cannabinoid therapeutic.
  • the non-cannabinoid therapeutic compound may comprise or be dextromethorphan. Subsequent to the administration, the subject may be characterized by at least a partial remission of the condition.
  • a subject may have a condition that may be mitigated through administering dextromethorphan (e.g., a cough).
  • dextromethorphan e.g., a cough
  • the subject may be characterized by decreased inflammation and enhanced liver protection.
  • Administering the co-therapeutic composition comprising a cannabinoid and dextromethorphan may improve the treatment or reduce one or more negative effects of the non-cannabinoid therapeutic.
  • administration of the co-therapeutic composition may improve the treatment of the cough of the subject by decreasing inflammation.
  • administration of the co- therapeutic composition comprising a cannabinoid and dextromethorphan provides enhanced liver protection compared to administration of dextromethorphan individually.
  • dextromethorphan may be stereoisomer, or prodrug thereof.
  • a co-therapeutic composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound may be administered to a subject.
  • the subject may have or be suspected of having a condition, which treatment of the condition may comprise administration of the non-cannabinoid therapeutic compound.
  • the treatment of the condition may be improved by administration of the co-therapeutic compound comprising a cannabinoid and the non-cannabinoid therapeutic.
  • the non-cannabinoid therapeutic compound may comprise or be an NSAID (e.g., ibuprofen, acetaminophen, or naproxen).
  • the subject may be characterized by at least a partial remission of the condition.
  • a subject may have a condition (e.g. pain, inflammation, fever, headache, or arthritis) that may be mitigated through administering an NSAID.
  • the subject may be characterized by decreased inflammation and enhanced liver protection.
  • Administering the co-therapeutic composition comprising a cannabinoid and an NSAID may improve the treatment or reduce one or more negative effects of the non-cannabinoid therapeutic.
  • administration of the co- therapeutic composition may improve the treatment of the condition by decreasing inflammation.
  • administration of the co-therapeutic composition comprising a cannabinoid and an NSAID provides enhanced liver protection compared to administration of an NSAID individually.
  • ibuprofen may salt, stereoisomer, or prodrug thereof.
  • acetaminophen may salt, isomer, or prodrug thereof.
  • naproxen may salt, stereoisomer, or prodrug thereof.
  • a co-therapeutic composition of the present disclosure comprising a cannabinoid and a non-cannabinoid therapeutic compound may be administered to a subject.
  • the subject may have or be suspected of having a condition, which treatment of the condition may comprise administration of the non-cannabinoid therapeutic compound.
  • the non-cannabinoid therapeutic compound may comprise or be a benzodiazepine (e.g., alprazolam, estazolam, flunitrazepam, clonazepam, lormetazepam, midazolam, lorazepam, nitrazepam, and temazepam, chlordiazepoxide, clorazepate, diazepam, lorazepam, halazepam, oxazepam, prazepam, or quazepam).
  • the subject may be characterized by at least a partial remission of the condition.
  • a subject may have a condition (e.g., anxiety, panic attacks, depression, insomnia, seizures, or naseua) that may be mitigated through administration of a benzodiazepine.
  • a condition e.g., anxiety, panic attacks, depression, insomnia, seizures, or naseua
  • the subject may be characterized by one or more of improved anxiolytic effects, lower addiction potential, and protection of the subject’s liver and brain as compared to administration of the benzodiazepine individually.
  • diazepam may be , or a salt, isomer, or prodrug thereof.
  • alprazolam may r prodrug thereof.
  • the structure of clonazepam may be , or a salt, isomer, or prodrug thereof.
  • the structure of temazepam may be or a salt, isomer, or prodrug thereof.
  • the co-therapy of (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, as disclosed herein can promote or cause a unique therapeutic effect (e.g., a synergistic effect, or a different effect not elicited by either (i) or (ii) alone in a subject).
  • the co-therapy can enhance efficacy (e.g., therapeutic efficacy) of (i) and/or (ii) by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more, as compared to treatment with either (i) or (ii) alone.
  • the co-therapy can elicit a therapeutic pathway (e.g., a cellular signaling pathway) that is not activated by treatment with either (i) or (ii) alone.
  • the co-therapy of (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, as disclosed herein can enhance efficacy (i.e., enhance overall outcome) of either (i) or (ii) alone in a subject.
  • the co-therapy of (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, as disclosed herein can enhance therapeutic window (e.g., a range of drug dosages which can treat disease effectively without having toxic effects) of either alone or both of (i) or (ii) in a subject.
  • the co-therapy can increase the therapeutic window of the one or more non- cannabinoid therapeutic compounds in the subject by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more, as compared to treatment with the one or more non-cannabinoid therapeutic compounds in absence of the one or more cannabinoid compounds.
  • the co-therapy of (i) one or more cannabinoid compounds and (ii) one or more non-cannabinoid therapeutic compounds, as disclosed herein can delay, reduce, or prevent side effects (e.g., off-target effects, toxicity, addiction, etc.) of either (i) or (ii) alone in a subject.
  • the co-therapy can reduce side effects of the one or more non-cannabinoid therapeutic compounds in the subject by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or more, as compared to treatment with the one or more non-cannabinoid therapeutic compounds in absence of the one or more cannabinoid compounds.
  • the present disclosure provides a composition comprising a plurality of microcapsules, wherein an individual microcapsule of the plurality comprises one or more therapeutic compositions, and wherein the microcapsules are not liposomes or micelles.
  • the present disclosure provides a composition comprising a plurality of microcapsules, wherein an individual microcapsule of the plurality of microcapsules comprises one or more therapeutic compositions, and wherein the composition has a shelf halflife of at least 30 days.
  • the present disclosure provides food products that are rich in therapeutic compositions.
  • compositions of the present disclosure can comprise microcapsules.
  • Microcapsules can comprise components discussed elsewhere in this disclosure, such as a mushroom, fulvic acid, L-Theanine, Fish Oil, pregnenolone, phenyl ethyl amine (PEA), tulsi, lemon balm, passion flower, terpene compounds, blue lotus, cacao, maca, schizandra, Siberian ginseng, kava, skullcap, valerian, hops, California poppy, catuba, epidmedium, pao d'arco, ashwaganda, ginko, albiza, reishi, lion's mane, maitake, chaga, vitamin C, turmeric, cannabinoid compounds, cannabidiol (CBD), tetrahydrocannabinol (THC), bioperine, and xanthohumol oil-based compounds, and others, in microencapsulated form.
  • PDA phenyl ethyl
  • compositions can be encapsulated without the use of liposomes. In some cases, compositions can be encapsulated without the use of micelles. In some cases, compositions can be encapsulated without the use of liposomes or micelles.
  • Compounds of the composition can exist within a microcapsule in forms including but not limited to liquid, gel, semi-solid, and solid. Microcapsules of compositions disclosed herein can further be processed into forms including but not limited to solids, powders, liquids, suspensions, gels, tablets, foods, lotions, cosmetics, and other forms discussed in this disclosure.
  • Microencapsulation can be performed with a microencapsulation device, including microfluidic droplet generation or encapsulation devices.
  • An exemplary microencapsulation device is described, for example, in U.S. Patent No. 7,482,152, incorporated here by reference in its entirety.
  • Microfluidic droplets or emulsions can be generated by flow of a fluid to be encapsulated with an immiscible carrier fluid.
  • an oil fluid to be encapsulated can be flowed with an aqueous carrier fluid, or an aqueous fluid to be encapsulated can be flowed with an oil carrier fluid.
  • Air can also be used as a fluid.
  • Microfluidic droplet generators useful for microencapsulation include those employing co-flowing streams, cross-flowing streams (e.g., flow of streams at a T-junction), flow focusing, flow through perforated plates, and flow through nozzles.
  • Droplet size can be controlled by parameters including device geometry, relative flow rates of the fluid streams, and operating pressure.
  • FIG. 1A shows an example of a droplet generator.
  • a first phase e.g., oil
  • the first phase from the first fluid chamber 1802 intersects with a second phase (e.g., aqueous phase) from a second fluid chamber 1806, which is transferred along a fluid channel section 1808 to an intersection 1810 with the fluid channel section 1804.
  • a second phase e.g., aqueous phase
  • the first phase from the first fluid chamber 1802 arrives at intersection 1810 from two different and substantially opposite directions
  • the second phase arrives at the intersection along only a single path that is substantially perpendicular to both directions of travel of the arriving first phase fluid.
  • droplets in the second phase are generated in a first phase background (e.g., a water-in-oil emulsion) and transferred along a fluid channel section 1812 to a third fluid chamber 1814, where the emulsion can be temporarily stored and/or transferred to another location.
  • the phases can be reversed, for example, such that the droplets in the first phase are generated in a second phase background (e.g., an oil-in-water emulsion).
  • FIG. IB shows another example of a droplet generator.
  • a first phase e.g., oil
  • Fluid channel section 1818 intersects with a fluid channel section 1822 that transfers a second phase (e.g., aqueous) fluid from a second fluid chamber 1820, at intersection 1824.
  • a second phase e.g., aqueous
  • the first phase from the first fluid chamber 1816 arrives at intersection 1810 from two different directions, but unlike in configuration 1800, the fluid does not arrive from substantially opposite (antiparallel) directions.
  • configuration 1815 may include first phase fluid channels that intersect a second phase fluid channel at any desired angle or angles.
  • the first phase fluid flowing through channel sections 1818 and the second phase fluid flowing through channel section 1822 can combine to form an emulsion of droplets in the second phase suspended in a first phase background (e.g., water-in- oil emulsion).
  • a first phase background e.g., water-in- oil emulsion
  • the droplets then may be transferred along a fluid channel section 1826 to a third fluid chamber 1828, for storage and/or transfer to another location.
  • the phases can be reversed, for example, such that the droplets in the first phase are generated in a second phase background (e.g., an oil-in-water emulsion).
  • FIG. 1C shows an example of a microfluidic structure.
  • the arrows within the depicted fluid channels indicate the direction of fluid flow within each channel.
  • fluid chambers for receiving and/or storing oil, water, and any generated emulsion are not depicted, these chambers or at least some source of oil and aqueous fluid may be present in a cartridge containing any of the depicted configurations.
  • the fluid channels and any associated chambers may be formed by any suitable method, such as injection molding complementary sections of thermoplastic as described previously.
  • a first phase fluid traveling along channel 1852 intersects with a second phase fluid traveling along channel 1854 at intersection 1856, to produce second phase-in-first phase emulsions (e.g., water-in-oil, oi-in- water, etc.) that travels along outgoing fluid channel 1858.
  • Second phase-in-first phase emulsions e.g., water-in-oil, oi-in- water, etc.
  • Droplets formed in the T-junction configuration 1850 may be formed primarily by a shear mechanism rather than primarily by a compression mechanism. However, droplet formation may depend on many factors, including the channel diameters, fluid velocities, and fluid viscosities.
  • Microencapsulation can be performed at a range of operating parameters, such as different flow rates or pressures. Microencapsulation can be conducted at a pressure of at least about 10 pounds per square inch (psi), 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 200 psi, 300 psi, 400 psi, 500 psi, 600 psi, 700 psi, 800 psi, 900 psi, 1000 psi, 2000 psi, 3000 psi, 4000 psi, 5000 psi, 6000 psi, 7000 psi, 8000 psi, 9000 psi, 10000 psi, 15000 psi, 20000 psi, 25000 psi, 30000 psi, 35000
  • Microencapsulation can be conducted at a pressure of at most about 10 pounds per square inch (psi), 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 200 psi, 300 psi, 400 psi, 500 psi, 600 psi, 700 psi, 800 psi, 900 psi, 1000 psi, 2000 psi, 3000 psi, 4000 psi, 5000 psi, 6000 psi, 7000 psi, 8000 psi, 9000 psi, 10000 psi, 15000 psi, 20000 psi, 25000 psi, 30000 psi, 35000 psi, 40000 psi, 45000 psi, or 50000 psi.
  • Microencapsulation can be conducted at a pressure of about 10 pounds per square inch (psi), 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 200 psi, 300 psi, 400 psi, 500 psi, 600 psi, 700 psi, 800 psi, 900 psi, 1000 psi, 2000 psi, 3000 psi, 4000 psi, 5000 psi, 6000 psi, 7000 psi, 8000 psi, 9000 psi, 10000 psi, 15000 psi, 20000 psi, 25000 psi, 30000 psi, 35000 psi, 40000 psi, 45000 psi, 50000 psi, or more.
  • Microencapsulation can be conducted at a flow rate of at least about 1 milliliter per minute (mL/min), 2 mL/min 3 mL/min, 4 mL/min, 5 mL/min, 6 mL/min, 7 mL/min, 8 mL/min, 9 mL/min, 10 mL/min, 20 mL/min, 30 mL/min, 40 mL/min, 50 mL/min, 60 mL/min, 70 mL/min, 80 mL/min, 90 mL/min, 100 mL/min, 110 mL/min, 120 mL/min, 130 mL/min, 140 mL/min, 150 mL/min, 160 mL/min, 170 mL/min, 180 mL/min, 190 mL/min, 200 mL/min, 210 mL/min, 220 mL/min, 230 mL/min, 240 mL
  • Microencapsulation can be conducted at a flow rate of at most about 1 milliliter per minute (mL/min), 2 mL/min 3 mL/min, 4 mL/min, 5 mL/min, 6 mL/min, 7 mL/min, 8 mL/min, 9 mL/min, 10 mL/min, 20 mL/min, 30 mL/min, 40 mL/min, 50 mL/min, 60 mL/min, 70 mL/min, 80 mL/min, 90 mL/min, 100 mL/min, 110 mL/min, 120 mL/min, 130 mL/min, 140 mL/min, 150 mL/min, 160 mL/min, 170 mL/min, 180 mL/min, 190 mL/min, 200 mL/min, 210 mL/min, 220 mL/min, 230 mL/min, 240 mL
  • Microencapsulation can be conducted at a flow rate of about 1 milliliter per minute (mL/min), 2 mL/min 3 mL/min, 4 mL/min, 5 mL/min, 6 mL/min, 7 mL/min, 8 mL/min, 9 mL/min, 10 mL/min, 20 mL/min, 30 mL/min, 40 mL/min, 50 mL/min, 60 mL/min, 70 mL/min, 80 mL/min, 90 mL/min, 100 mL/min, 110 mL/min, 120 mL/min, 130 mL/min, 140 mL/min, 150 mL/min, 160 mL/min, 170 mL/min, 180 mL/min, 190 mL/min, 200 mL/min, 210 mL/min, 220 mL/min, 230 mL/min, 240 mL/min
  • Droplet generators can employ multiple parallel droplet generation operations in parallel.
  • a droplet generator e.g., a plate, a device with channels
  • a droplet generator can employ at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more droplet generating features (e.g., holes, channels, nozzles).
  • a droplet generator can employ at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 droplet generating features.
  • a droplet generator can employ about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more droplet generating features.
  • Microencapsulation can be performed via an emulsification process.
  • compositions can be emulsified in a mixer, such as an agitator, impeller, centrifugal mixer, or high-shear mixer.
  • High-shear mixers can include batch high-shear mixers and inline high-shear mixers (e.g., rotor-stator mixers).
  • Emulsification can also be conducted without a mixer, by combining fluids thermodynamically favored to form an emulsion, optionally with the aid of one or more emulsifiers or surfactants.
  • Microencapsulation processes can be conducted with the aid of one or more emulsifiers or surfactants.
  • Emulsifiers and surfactants can include but are not limited to saponins (e.g., quillaja tree extract such as Q-NATURALE®, yucca extract), lecithin, soy lecithin, mustard seed hull extract, sodium stearoyl lactylate, polysorbate 20, and combinations thereof.
  • Microcapsules can comprise one or more stabilizers or gelling agents, which can be used to stabilize a microcapsule or emulsion.
  • Stabilizers or gelling agents can include but are not limited to alginate (also algin or alginic acid) and agar.
  • Alginate can be used in a variety of forms, including but not limited to inorganic salts such as sodium alginate, potassium alginate, calcium alginate, and combinations thereof.
  • Alginate can be derived from sources such as seaweed (e.g., Macrocystis pyrifera, Ascophyllum nodosum, Laminaria spp.) or bacteria (e.g., Pseudomonas spp., Azotobacter spp.).
  • Cross-linking agents or solutions such as calcium chloride, can be used to stabilize or gel microcapsules.
  • Microcapsules can be characterized by a size (e.g., a diameter).
  • the microcapsule size can be about 0.154 micrometers.
  • the microcapsule size can be less than or equal to about 0.154 micrometers.
  • the microcapsule size can be greater than or equal to about 0.154 micrometers.
  • the microcapsule size can be about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7,
  • the microcapsule size can be less than or equal to about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, or 500 micrometers.
  • the microcapsule size can be greater than or equal to about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, or 500 micrometers.
  • the microcapsule size can be from about 0.1 to about 0.2 micrometers.
  • the microcapsule size can be from about 0.05 to about 0.25 micrometers.
  • the microcapsule size can be from about 0.05 to about 0.55 micrometers.
  • the microcapsule size can be from about 0.05 to about 1 micrometers.
  • the size distribution in a population of microcapsules can be homogeneous or substantially homogeneous.
  • a population of microcapsules can be characterized by dispersity, or poly dispersity index (PDI), of less than or equal to about 20, 19, 18, 17, 16, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6,
  • PDI poly dispersity index
  • compositions of the present disclosure can comprise solid compositions (e.g., tablets, pills, etc.).
  • FIGs. 5A-5D show different examples of the solid composition (e.g., tablets) as disclosed herein.
  • the tablet can comprise a mixture (e.g., homogeneous or heterogeneous mixture) of a non-cannabinoid therapeutic compound 501 and a cannabinoid compound 503.
  • the tablet can comprise a first layer comprising a non- cannabinoid therapeutic compound 501 and a second layer comprising a cannabinoid compound 503.
  • the tablet can comprise a middle layer comprising a non- cannabinoid therapeutic compound 501 that is disposed between at least two layers comprising a cannabinoid compound 503.
  • the tablet can comprise a first layer comprising a non-cannabinoid therapeutic compound 501, a third layer comprising a cannabinoid compound 503, and a second layer comprising a filler or a different therapeutic compound 505 that is disposed between the first layer and the second layer.
  • FIGs. 6A-6D show different examples of the solid composition (e.g., pills) as disclosed herein.
  • the pill can comprise a mixture (e.g., homogeneous or heterogeneous mixture) of a non-cannabinoid therapeutic compound 601 and a cannabinoid compound 603.
  • the pill can comprise a first layer comprising a non- cannabinoid therapeutic compound 601 and a second layer comprising a cannabinoid compound 603.
  • the pill can comprise a middle layer comprising a non-cannabinoid therapeutic compound 601 that is disposed between at least two layers comprising a cannabinoid compound 603.
  • the pill can comprise a first layer comprising a non- cannabinoid therapeutic compound 601, a third layer comprising a cannabinoid compound 603, and a second layer comprising a filler or a different therapeutic compound 605 that is disposed between the first layer and the second layer.
  • compositions of the present disclosure may comprise a variety of compounds, such as a mushroom, fulvic acid, L-Theanine, Fish Oil, pregnenolone, phenyl ethyl amine (PEA), tulsi, lemon balm, passion flower, terpene compounds, blue lotus, cacao, maca, schizandra, Siberian ginseng, kava, skullcap, valerian, hops, California poppy, catuba, epidmedium, pao d'arco, ashwaganda, ginko, albiza, reishi, lion's mane, maitake, chaga, vitamin C, turmeric, cannabinoid compounds, cannabidiol (CBD), tetrahydrocannabinol (THC), bioperine, xanthohumol oil-based compounds, and others, and/or a combination thereof.
  • PDA phenyl ethyl amine
  • tulsi lemon balm
  • Cannabinoids utilized in the compositions disclosed herein include but are not limited to cannabigerol-type (CBG), cannabigerolic acid (CBGA), cannabigerolic acid monomethylether (CBGAM), cannabigerol monomethyl ether (CBGM), cannabichromene-type (CBC), cannabichromanon (CBCN), cannabichromenic acid (CBCA), cannabichromevarin-type (CBCV), cannabichromevarinic acid (CBCVA), cannabidiol-type (CBD), tetrahydrocannabinoltype (THC), iso-tetrahydrocannabinol-type (iso-THC), cannabinol-type (CBN), cannabinolic acid (CBNA), cannabinol methylether (CBNM), cannabinol-C4 (CBN-C4), cannabinol-C2 (CBN- C2), cann
  • Cannabinoids used in compositions of the present disclosure can be derived from various sources, including but not limited to hemp (e.g. hemp stalk, hemp stem, hemp seed), cannabis (e.g., cannabis flower, cannabis leaf, cannabis stalk, cannabis stem, cannabis seed), Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, black truffle, Syzygium aromaticum (cloves), Rosmarinus oficinalis, basil, oregano, black pepper, lavender, true cinnamon, malabathrum, cananga odorata, copaifera spp., and hops.
  • hemp e.g. hemp stalk, hemp stem, hemp seed
  • cannabis e.g., cannabis flower, cannabis leaf, cannabis stalk, cannabis stem, cannabis seed
  • Echinacea purpurea echinacea angustifolia
  • Echinacea pallida e.g
  • Encapsulated cannabinoids can be present in a quantity of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated cannabinoids can be present in a quantity of at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated cannabinoids can be present in a quantity of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated cannabinoids can be present in a quantity of from about 1 to about 10 micrograms per microcapsule.
  • Encapsulated cannabinoids can be present in a quantity of at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated cannabinoids can be present in a quantity of at most about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated cannabinoids can be present in a quantity of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of from about 50 to about 150 milligrams.
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Cannabinoids can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • the cannabinoids of the compositions disclosed herein can comprise cannabidiol-class compounds, including but not limited to cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabidiorcol (CBD-Ci), and combinations thereof.
  • CBD cannabidiol
  • CBD cannabidiolic acid
  • CBDDM cannabidiol monomethylether
  • CBD-C4 cannabidiol-C4
  • CBD-C4 cannabidivarin
  • CBDV cannabidivarinic acid
  • CBD-Ci cannabidiorcol
  • CBD can comprise delta-1 -cannabidiol, delta-2- cannabidiol, delta-3- cannabidiol, delta-3,7- cannabidiol, delta-4- cannabidiol, delta-5- cannabidiol, delta-6- cannabidiol, and combinations thereof.
  • Encapsulated cannabidiol compounds can be present in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated cannabidiol compounds can be present in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated cannabidiol compounds can be present in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated cannabidiol compounds can be present in a quantity of from about 1 to about 10 micrograms per microcapsule.
  • Encapsulated cannabidiol compounds can be present in a quantity of at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated cannabidiol compounds can be present in a quantity of at most about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated cannabidiol compounds can be present in a quantity of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of from about 50 to about 150 milligrams.
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Cannabidiol compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • compositions of the present disclosure can comprise tetrahydrocannabinol (THC) as a type of cannabinoids.
  • THC can comprise delta-9-THC, delta-8-THC, and combinations thereof.
  • THC can comprise delta-6a,7-tetrahydrocannabinol, delta-7-tetrahydrocannabinol, delta- 8-tetrahydrocannabinol, delta-9,11- tetrahydrocannabinol, delta-9- tetrahydrocannabinol, delta- 10-tetrahydrocannabinol, delta-6a,10a- tetrahydrocannabinol, and combinations thereof.
  • Delta-9- tetrahydrocannabinol can comprise stereoisomers including (6aR,10aR)-delta-9- tetrahydrocannabinol, (6aS, 10aR)-delta-9-tetrahydrocannabinol, (6aS, 10aS)-delta-9- tetrahydrocannabinol, (6aR,10aS)-delta-9-tetrahydrocannabinol, and combinations thereof.
  • THC compounds can be present in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated THC compounds can be present in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated THC compounds can be present in a quantity of from about 1 to about 10 micrograms per microcapsule. Encapsulated THC compounds can be present in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated THC compounds can be present in a quantity of at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated THC compounds can be present in a quantity of at most about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated THC compounds can be present in a quantity of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of from about 50 to about 150 milligrams.
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • THC compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • compositions of the present disclosure does not contain a psychoactive amount of THC.
  • cannabinoids in compositions of the present disclosure can contain less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.7%, 0.5%, 0.3%, or 0.1% THC relative to the total quantity of cannabinoid compounds.
  • the ratio of a non-THC cannabinoid (e.g., cannabidiol) to THC in a composition of the present disclosure is greater than or equal to about 1 : 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13: 1, 14: 1, 15:1, 16: 1, 17: 1, 18: 1, 19: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, or 100: 1.
  • compositions of the present disclosure contain less than 0.3% THC.
  • compositions of the present disclosure can comprise one or more terpene compounds, including but not limited to terpenoids such as monoterpenoids, sesquiterpenoids, diterpenoids, and triterpenoids.
  • Terpenes can be acyclic, monocyclic, or polycyclic.
  • Terpenes can include but are not limited to myrcene, limonene, linalool, /ra/z.s-ocimene, cz -ocimene, alpha-pinene, beta-pinene, alpha-humulene (alpha-caryophyllene), beta-caryophyllene, delta-3- carene, /ra/rs-gamma-bi sabol ene, c/.s-gamma-bisabolene, /ra/rs-alpha-farnesene, c/.s-beta- farnesene, beta-fenchol, beta-phellandrene, guajol, alpha-gualene, alpha-eudesmol, beta- eudesmol, gamma-eudesmol, terpinolene, alpha-selinene, beta-selinene, alpha-terpineol
  • Encapsulated terpenes can be present in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated terpenes can be present in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated terpenes can be present in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated terpene compounds can be present in a quantity of from about 1 to about 10 micrograms per microcapsule.
  • Encapsulated terpenes can be present in a quantity of at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated terpenes can be present in a quantity of at most about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated terpenes can be present in a quantity of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of from about 50 to about 150 milligrams.
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Terpene compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Non-cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Non-cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • a product such as a drug unit dose or a food product
  • Non- cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500 milligrams (mg).
  • Non-cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of from about 50 to about 150 milligrams.
  • Non- cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Non-cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • Non-cannabinoid therapeutic compounds can be present in the composition (e.g., a product, such as a drug unit dose or a food product), in a quantity of about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the product.
  • a product such as a drug unit dose or a food product
  • an amount of a cannabinoid compound can be greater than an amount of a non-cannabinoid therapeutic compound by at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 2,000%., or more by weight.
  • an amount of a cannabinoid compound can be greater than an amount of a non-cannabinoid therapeutic compound by at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 2,000%., or more by weight.
  • an amount of a cannabinoid compound can be less than an amount of a non-cannabinoid therapeutic compound by at least about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 2,000%., or more by weight.
  • an amount of a cannabinoid compound can be less than an amount of a non-cannabinoid therapeutic compound by at most about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 2,000%., or more by weight.
  • an amount of a cannabinoid compound can be approximately the same as an amount of a non-cannabinoid therapeutic compound in the composition as disclosed herein.
  • Encapsulated non-cannabinoid therapeutic compounds can be present in a quantity of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated non- cannabinoid therapeutic compounds can be present in a quantity of at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated non-cannabinoid therapeutic compounds can be present in a quantity of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 nanograms, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 micrograms per microcapsule.
  • Encapsulated non-cannabinoid therapeutic compounds can be present in a quantity of from about 1 to about 10 micrograms per microcapsule.
  • Encapsulated non- cannabinoid therapeutic compounds can be present in a quantity of at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated non-cannabinoid therapeutic compounds can be present in a quantity of at most about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • Encapsulated non- cannabinoid therapeutic compounds can be present in a quantity of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of a microcapsule.
  • compositions of the present disclosure can be enriched in cannabinoids compared to hemp oil.
  • a composition can comprise hemp oil and cannabinoids from plant sources such as extracts (e.g., hemp extract) and essential oils.
  • a composition can comprise about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% greater concentration of cannabinoids compared to hemp oil.
  • compositions of the present disclosure can be enriched in cannabidiol compounds compared to hemp oil.
  • a composition can comprise hemp oil and cannabidiol compounds from plant sources such as extracts (e.g., hemp extract) and essential oils.
  • a composition can comprise about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% greater concentration of cannabidiol compounds compared to hemp oil.
  • compositions of the present disclosure can be enriched in THC compounds compared to hemp oil.
  • a composition can comprise hemp oil and THC compounds from plant sources such as extracts (e.g., hemp extract) and essential oils.
  • a composition can comprise about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% greater concentration of THC compounds compared to hemp oil.
  • compositions of the present disclosure can be enriched in terpenes compared to hemp oil.
  • a composition can comprise hemp oil and terpenes from plant sources such as extracts (e.g., hemp extract) and essential oils.
  • a composition can comprise about 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% greater concentration of terpenes compared to hemp oil.
  • Compounds included in the compositions of the present disclosure can be derived from various sources. Compound sources can be natural, such as plant extracts or essential oils.
  • Compounds in the compositions of the present disclosure can be derived from hemp oil, including cannabinoid compounds, THC compounds, and terpene compounds.
  • Compounds in the compositions of the present disclosure can be derived from essential oils, including but not limited to those essential oils discussed further in this disclosure. These compounds can include cannabinoid compounds and terpene compounds.
  • all the compounds or ingredients in a composition are natural or naturally-derived. In some cases, all the compounds or ingredients in a composition are vegetarian. In some cases, all the compounds or ingredients in a composition are vegan.
  • Terpenes and/or essential oils in compositions of the present disclosure can be selected to provide benefits for particular conditions or subjects.
  • Terpenes and/or essential oils can be employed in combination with each other, as well as in combination with cannabinoids, for example to target treatment of particular conditions.
  • cannabinoids for example to target treatment of particular conditions.
  • terpinolene, terpineol and linalool or lavender, valerian and jasmine essential oils can be combined with cannabinoids or cannabis extract to act as a sleep aid or treat sleep disorders.
  • Alpha-pinene can be used as an anti-inflammatory, an anti angiogenic, an anti-ulcer agent, and a bronchodilator.
  • Linalool can be used for reducing anxiety, reducing inflammation (e.g., lung inflammation), to improve Alzheimer’s disease or symptoms thereof, as a sedative, an analgesic, an anti-microbial, an antibacterial, and an anti-epileptic.
  • Myrcene can be used as an antibacterial, a neuroprotective agent, an antinociceptive, an analgesic, and to alleviate neuropathic pain, peptic ulcer disease, and inflammation. Depending on concentration, myrcene can be used as a sedative (e.g., over 0.5% myrcene) or to provide energizing effects (e.g., less than 0.5% myrcene).
  • Limonene can be used to reduce anxiety and depression, to dissolve cholesterol- containing gallstones, to neutralize gastric acid, support normal peristalsis, relieve heartburn and gastroesophageal reflux, to improve immune function, and as a chemopreventative against cancer.
  • Ocimene can be used as an antifungal agent, an antitumor agent, and a cyctotoxic agent.
  • Terpinolene can be used for antioxidant, mood regulation, central nervous system (CNS) regulation, anti-inflammatory, anti -diarrheal, anti-filarial, anti-fungal, antimalarial, anti- amoebic, anti-bacterial, cytotoxic, and anticancer effects.
  • CNS central nervous system
  • Terpineol can be used to relax a subject, to aid digestion and improve gastrointestinal disorders, and to relieve influenza, bronchitis, cough, nasal congestion, and sinusitis.
  • Beta-caryophyllene can be used as an anti-inflammatory agent, an anti-tumor agent, and an analgesic.
  • Geraniol can be used to reduce or protect against neuropathy, as an antidepressant, to suppress angiogenesis, to improve anti-cancer agent efficacy, to suppress growth of cancer cells (e.g., lung cancer), as a chemopreventive against cancer, to reduce inflammation and apoptosis (e.g., in liver cells), to reduce oxidative stress, as an antioxidant, and as an antimicrobial.
  • cancer cells e.g., lung cancer
  • apoptosis e.g., in liver cells
  • oxidative stress as an antioxidant, and as an antimicrobial.
  • Alpha-humulene can be used as an appetite suppressant, an anti-inflammatory agent, an insect repellant, an antibacterial, an antioxidant, and an allelopathic agent.
  • Phellandrene can be used as an antidepressant and an antihyperalgesic.
  • Carene can be used as an antioxidant, an antiproliferative, an antimicrobial, and to reduce excess body fluid production, such as of tears, mucous, or sweat.
  • Terpinene can be used as an antioxidant, an anti-inflammatory, an antimicrobial, an antiproliferative, to reduce oxidative stress, and to manage diabetes.
  • Fenchol can be used as an antibacterial agent, an antimycobacterial, an antimicrobial, and an antioxidant.
  • Borneol can be used to alleviate hyperalgesia, as a TRPA1 inhibitor, an antiinflammatory agent, and an anti -nociceptive agent.
  • Bisabolol can be used as an anti-cancer agent, such as to induce apoptosis in leukemia, an anti-tumor agent (e.g., pancreatic cancer), and an antigenotoxicity agent.
  • Phytol can be used to relax a subject, such as by inhibiting degradation of GABA, as an anxiolytic, to resist menadione-induced oxidative stress, and as an antimicrobial.
  • Camphene can be used for pain relief, as an antioxidant, to induce apoptosis in cancer cells (e.g., melanoma), an antitumor agent, and an antibacterial.
  • cancer cells e.g., melanoma
  • an antitumor agent e.g., melanoma
  • an antibacterial e.g., melanoma
  • Sabinene can be used as an antioxidant, an antimicrobial, an anticancer agent (e.g., oral, liver, lung, colon, melanoma, and leukemic cancer), to aid liver function, aid digestion, relieve arthritis, and relieve skin conditions.
  • an antimicrobial e.g., oral, liver, lung, colon, melanoma, and leukemic cancer
  • Camphor can be used to improve skin healing (e.g., reconstructed human epidermis), as a local anesthetic, a muscle relaxant, an antipathogenic, and an antimicrobial agent.
  • Isobomeol can be used as an antioxidant, a cytotoxic, a DNA-protective, to inhibit herpes simplex virus type 1, and to inhibit HIV.
  • Menthol can be used as an analgesic, to desensitize a3p4 nicotinic acetylcholine receptors, as an antinociceptive, and as an anti-inflammatory agent.
  • Nerolidol can be used as an antifungal agent, an antimicrobial agent, an antioxidant, and an antimalarial agent.
  • Guaiol can be used as an antimicrobial agent, an antifungal agent, and an antibiotic.
  • Isopulegol can be used as a gastroprotective agent, an anti-inflammatory agent, to enhance permeability for transdermal administration of compounds, and to reduce the severity of seizures.
  • Geranyl acetate can be used as an antimicrobial agent, an antibacterial, and an antioxidant.
  • Cymene can be used as an anti-inflammatory agent, an anti-hyperalgesic, an antioxidant, an anti-diabetic, to aid in weight loss, to aid immune disorders, and to protect against acute lung injury.
  • Eucalyptol can be used as an antifungal agent, to alleviate inflammation (e.g., lung inflammation), an antioxidant, and an anticancer agent.
  • Pulegone can be used to enhance skin permeability, as an insecticide, and an antioxidant.
  • compositions of the present disclosure can comprise one or more essential oils or essential oil compounds.
  • Essential oils can include, but are not limited to: Linalool; B- Caryophyllene; B-Myrcene; D-Limonene; Humulene; a-Pinene; Ylang Ylang (Cananga odorata); Yarrow (Achillea millefolium); Violet (Viola odorata); Vetiver (Vetiveria zizanoides); Vanilla (Vanilla plantifolia); Tuberose (Polianthes tuberosa); Thyme (Thymus vulgaris L.); Tea Tree (Melaleuca alternifolia); Tangerine (Citrus reticulata); Spruce, Black (Picea mariana); Spruce (Tsuga Canadensis); Spikenard (Nardostachys jatamansi); Spearmint (Mentha spicata); Sandalwood (Santalum
  • compositions of the present disclosure can comprise one or more additional ingredients, including but not limited to mushrooms or mushroom derivative products (e.g., reishi mushroom, chaga mushroom, maitake mushroom, oyster mushroom, cordyceps), maca (Lepidium meyenii), he sho wu (also he show wu or shou wu chih), superfoods or superfood derivative products (e.g., blueberries, acai berries, inca berries, goji berries, camucamu, coconut, lucuma, kale, cacao (e.g., cacao powder, cacao butter), sacha inchi, chia, flax, hemp, amaranth, quinoa, moringa oleifera), and combinations thereof.
  • mushrooms or mushroom derivative products e.g., reishi mushroom, chaga mushroom, maitake mushroom, oyster mushroom, cordyceps
  • maca Lepidium meyenii
  • he sho wu also he show wu or
  • compositions of the present disclosure can be extracted by a variety of methods.
  • extraction can be performed by maceration, infusion, decoction, percolation, Soxhlet extraction, pressurized solvent extraction, counter current extraction, ultrasonication, or supercritical fluid (e.g., carbon dioxide) extraction.
  • supercritical fluid e.g., carbon dioxide
  • compounds used in compositions of the present disclosure are extracted via supercritical fluid (e.g., carbon dioxide) extraction.
  • supercritical fluid e.g., carbon dioxide
  • cannabinoid compounds can be extracted from hemp (e.g., hemp stalk and hemp stems) using supercritical carbon dioxide extraction.
  • compositions of the present disclosure can comprise pregnenolone, including derivatives thereof.
  • Pregnenolone can help protect a subject from cannabis intoxication, for example from THC.
  • Pregnenolone or derivatives thereof can be formulated to be water soluble.
  • a composition of the present disclosure can comprise between about 1 and 50 milligrams (mg) of pregnenolone or derivatives thereof.
  • a unit dosage of the present disclosure can comprise between about 1 and 50 milligrams (mg) of pregnenolone.
  • Compositions of the present disclosure (e.g., unit dosages) can comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg of pregnenolone.
  • Compositions of the present disclosure can comprise at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg of pregnenolone.
  • Compositions of the present disclosure can comprise at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg of pregnenolone.
  • compositions comprising pregnenolone can be used in combination with any other compounds, ingredients, or formulations described herein, including esters, cyclodextrin complexes, microcapsules (e.g., sodium alginate microcapsules), immediate release formulations, delayed or extended release formulations, transbuccal formulations, and sublingual formulations.
  • compositions of the present disclosure can be used to treat various diseases or conditions in subjects (e.g., humans, mammals, vertebrates), including but not limited to ALS, Alzheimer’s, antibacterial resistant infections, anxiety, atherosclerosis, arthritis, asthma, cancer, colitis, Crohn’s, diabetes, depression, endocrine disorders, epilepsy, seizures, fibromyalgia, glaucoma, heart disease, Huntington’s, inflammation, irritable bowel syndrome (IBS), kidney disease, liver disease, motion sickness, nausea, neurodegeneration, neuropathic pain, neuropathy, obesity, obsessive compulsive disorder (OCD), osteoporosis, Parkinson’s, prion diseases, Mad Cow disease, post-traumatic stress disorder (PTSD), rheumatism, schizophrenia, sickle cell anemia, skin conditions (e.g., psoriasis, dermatitis, allergic inflammation, chronic pruritus), sleep disorders (e.g., sleep-wake disorders, apne
  • ALS
  • an oil-based composition e.g., hemp oil
  • a drying or powdering agent such as cyclodextrin.
  • a powder composition can be provided on its own.
  • a powder composition can be provided in another product, such as a food product, cosmetic product, or other products and compositions such as those disclosed herein.
  • the compositions of the present disclosure can be provided in any suitable form, including but not limited to a liquid form, a gel form, a semi-liquid (e.g., a liquid, such as a viscous liquid, containing some solid) form, a semi-solid (a solid containing some liquid) form, or a solid form.
  • compositions can be provided in, for example, a tablet form, a capsule form, a food form a chewable form, a non-chewable form, a transbuccal form, a sublingual form, a slow- release form, a non-slow-release form, a sustained release form, or a non-sustained-release form.
  • the compositions of the present disclosure can be administered in any oral dosage form, including liquid dosage forms (e.g., a suspension or slurry), and oral solid dosage forms (e.g., a tablet or bulk powder).
  • Tablets can include tablets, caplets, capsules, including soft gelatin capsules, and lozenges. Tablets can further comprise suitable binders, lubricants, diluents, disintegrating agents, colorants, flavoring agents, flow-inducing agents, and melting agents.
  • compositions of the present disclosure can be administered transdermally, such as via a patch.
  • the compositions of the present disclosure can be administered intravenously.
  • the compositions of the present disclosure can be administered topically.
  • the compositions of the present disclosure can be administered via exposure to an aqueous solution, such as a subject immersing in a float tank.
  • the compositions of the present disclosure can be formulated as a bath salt or liquid bath product, which can be dissolved or dispersed in water (e.g., a bath) for skin exposure, for example by immersion of the subject.
  • compositions of the present disclosure can be provided as cosmetics or personal care products, such as soaps (e.g., solid, bar, liquid, or foaming), hand sanitizer, lotions, massage oils masks, makeup, moisturizers, sunscreen, toothpaste, mouth wash, or throat spray.
  • soaps e.g., solid, bar, liquid, or foaming
  • hand sanitizer e.g., solid, bar, liquid, or foaming
  • lotions e.g., lotion, massage oils masks, makeup, moisturizers, sunscreen, toothpaste, mouth wash, or throat spray.
  • cannabinoids can provide benefits including reduction of inflammation in a subject.
  • compositions of the present disclosure can be provided as a food composition in combination with a food carrier, including but not limited to food bars (e.g., granola bars, protein bars, candy bars), cereal products (e.g., oatmeal, breakfast cereals, granola), bakery products (e.g., bread, donuts, crackers, bagels, pastries, cakes), dairy products (e.g., milk, yogurt, cheese), beverages (e.g., milk-based beverages, sports drinks, fruit juices, teas, soft drinks, alcoholic beverages, bottled waters), beverage mixes, pastas, grains (e.g., rice, corn, oats, rye, wheat, flour), egg products, snacks (e.g., candy, chips, gum, gummies, lozenges, mints, chocolate), meats, fruits, vegetables or combinations thereof.
  • food bars e.g., granola bars, protein bars, candy bars
  • cereal products e.g., oatmeal, breakfast cereals, granola
  • bakery products e
  • Food compositions can comprise solid foods.
  • Food compositions can comprise semi-solid foods.
  • Food compositions can comprise liquid foods.
  • a composition in a liquid form may be formulated from a dry mix, such as a dry beverage mix or a powder.
  • a dry mix may be suitable in terms of transportation, storage, or shelf life.
  • the composition can be formulated from the dry mix in any suitable manner, such as by adding a suitable liquid (e.g., water, milk, fruit juice, tea, or alcohol).
  • a food composition or food product can comprise a food bar, including but not limited to granola bars, protein bars, candy bars, and energy bars.
  • a food composition or food product can comprise a cereal product, including but not limited to oatmeal, flour (e.g., wheat flour, rice flour, com flour, barley flour), breakfast cereal, granola, bread, pasta, rice cakes, and popcorn.
  • a food composition or food product can comprise a bakery product, including but not limited to bread, pastries, brownies, cakes, pies, donuts, crackers, and muffins.
  • a food composition or food product can comprise a dairy product, including but not limited to milk, fermented milk, curd, whey, yogurt, cream, cheese, butter, clarified butter, ghee, and ice cream.
  • a food composition or food product can comprise a nut butter or seed butter, including but not limited to peanut butter, almond butter, cashew butter, hazelnut butter, macadamia nut butter, pecan butter, pistachio butter, walnut butter, pumpkin seed butter, sesame seed butter, soybean butter, and sunflower seed butter.
  • a nut butter or seed butter including but not limited to peanut butter, almond butter, cashew butter, hazelnut butter, macadamia nut butter, pecan butter, pistachio butter, walnut butter, pumpkin seed butter, sesame seed butter, soybean butter, and sunflower seed butter.
  • a food composition or food product can comprise an oil (e.g., a cooking oil), including but not limited to olive oil, coconut oil, vegetable oil, canola oil, corn oil, peanut oil, sunflower seed oil, almond oil, avocado oil, rice bran oil, cottonseed oil, flaxseed oil, linseed oil, grape seed oil, hemp oil, mustard oil, macadamia oil, palm oil, tea seed oil, walnut oil, margarine, lard, butter, clarified butter, ghee, or tallow.
  • a food composition or food product can comprise sports food products such as energy gels, sports drinks, energy powders, energy bars, energy shots, protein powders, and protein drinks (e.g., protein shakes).
  • a food composition or food product can comprise a beverage, including but not limited to water, electrolyte drinks, soda, coconut water, tea (e.g., Jun tea, black tea, green tea, white tea, herbal tea), coffee, a soft drink, an alcoholic beverage (e.g., cocktail, liquor, spirits, beer, wine, malt beverage), water, juice (e.g., apple juice, orange juice, tomato juice, vegetable juice, cranberry juice), a sports drink, electrolyte-enriched water, vitamin-enhanced water, a hangover-recovery drink, milk (e.g., dairy-based milk, coconut milk, almond milk, soy milk, hemp milk, rice milk, oat milk, cashew milk, hazelnut milk), and yogurt.
  • alcoholic beverage e.g., cocktail, liquor, spirits, beer, wine, malt beverage
  • juice e.g., apple juice, orange juice, tomato juice, vegetable juice, cranberry juice
  • milk e.g., dairy-based milk, coconut milk,
  • a food composition or food product can comprise a fungus or fermented food or drink, including but not limited to kifir (kefir), jun, amasi, amazake, appam, ayran, doogh, bagoong, brem, cheonggukjang, chicha, kombucha, fermented bean curd, kimchi, lassi, miso, poi, yakult, and yogurt.
  • kifir kefir
  • jun amasi
  • amazake appam
  • ayran doogh
  • bagoong brem
  • cheonggukjang chicha
  • kombucha fermented bean curd
  • kimchi lassi
  • miso poi
  • poi yakult, and yogurt.
  • compositions of the present disclosure can comprise pet or other animal products, such as animal food (e.g., dog food, cat food), treats, and nutritional supplements (e.g., liquids, sprays, or powders for application to food or water).
  • animal food e.g., dog food, cat food
  • nutritional supplements e.g., liquids, sprays, or powders for application to food or water.
  • These compositions can be formulated for or administered to domestic or pet animals (e.g., dogs, cats, small mammals, birds), livestock and other farm animals (e.g., cows, pigs, horses, sheep, goats), zoo animals, or any other vertebrates.
  • Compositions for administration to animals can be formulated with microencapsulated cannabinoid-rich oil or non-encapsulated cannabinoid-rich oil, alone or in combination with essential oils, terpenes, and other components described herein.
  • compositions for administration to animals can be mixed into feed or water, prepared for spraying application (e.g., mixed in glycerin), for intravenous administration (e.g., in a syringe or an IV bag), in salves, vitamins, liquid vitamin pumps, treats, or other forms.
  • spraying application e.g., mixed in glycerin
  • intravenous administration e.g., in a syringe or an IV bag
  • salves e.g., vitamins, liquid vitamin pumps, treats, or other forms.
  • compositions of the present disclosure can comprise an additional agent or agents, whether active or passive.
  • an agent include a sweetening agent, a flavoring agent, a coloring agent, a filling agent, a binding agent, a lubricating agent, an excipient, a preservative, or a manufacturing agent.
  • Additional pharmaceutically acceptable excipients in the case of pharmaceuticals or other additives (for non-pharmaceutical applications) can be added to the composition.
  • any generally accepted soluble or insoluble inert pharmaceutical filler (diluent) material can be included in the final product (e.g., a solid dosage form).
  • Such inert pharmaceutical filler can comprise a monosaccharide, a disaccharide, a polyhydric alcohol, inorganic phosphates, sulfates or carbonates, and combinations thereof.
  • suitable inert pharmaceutical fillers include sucrose, dextrose, lactose, xylitol, fructose, sorbitol, calcium phosphate, calcium sulfate, calcium carbonate, microcrystalline cellulose, and combinations thereof.
  • An effective amount of any generally accepted pharmaceutical lubricant, such as calcium or magnesium soaps, can be added.
  • compositions of the present disclosure can be administered to a subject.
  • Compositions can be administered in a variety of ways, including but not limited to oral and topical administration.
  • compositions of the present disclosure can provide one or more beneficial effects.
  • beneficial effects can include but are not limited to pain relief, reduced bacterial growth, reduced blood sugar levels, improved blood lipid and cholesterol profiles, increased fat burning, reduced appetite, stimulated appetite, reduced vomiting or nausea, reduced seizures or convulsions, antifungal effects, reduced inflammation, reduced arthritis (e.g., rheumatoid arthritis), reduced insomnia or aided sleep, reduced arterial blockage, inhibited cancer cell growth, improved psoriasis, tranquilizing effects, antispasmodic effects, reduced anxiety, bone growth promotion, reduced intestinal contractions, and nervous system protection.
  • Administering a composition of the present disclosure to a subject can improve a therapeutic window of the subject.
  • the improved therapeutic window may be compared to administration of the non-cannabinoid therapeutic compound individually.
  • Administering a composition of the present disclosure can mitigate a toxicity of the non-cannabinoid therapeutic compound, as compared to administering the non-cannabinoid therapeutic compound individually.
  • Any of the subject compositions can be provided in a unit dosage form.
  • a unit dosage is an amount of a compound, such as a cannabinoid compound delivered with other components (e.g., non-cannabinoid therapeutic compounds as disclosed herein), which is to be administered to a subject (e.g., orally, intravenously, etc.) at or about one time point.
  • Other components which can be included with a unit dosage include but are not limited to cosmetics, food carriers, food bars, baked goods, dairy products, oils, beverages, solid dosages (e.g., tablets or pills), or liquid dosages.
  • a unit dosage of a cannabinoid compound can be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).
  • a unit dosage of a cannabinoid compound can be at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).
  • a unit dosage of a cannabinoid compound can be at most about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).
  • a unit dosage of a non-cannabinoid therapeutic compound can be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).
  • a unit dosage of a non-cannabinoid therapeutic compound can be at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).
  • a unit dosage of a non-cannabinoid therapeutic compound can be at most about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more milligrams (mg).
  • a unit dosage can be an hourly dosage.
  • a unit dosage can be a daily dosage.
  • a unit dosage can provide about 1/24, 1/12, 1/8, 1/6, 1/4, 1/3, 1/2, or all of a daily dosage of one or more cannabinoids or at least one non-cannabinoid therapeutic compounds for a subject.
  • a unit dosage can take the form of a tablet, gel, liquid, food product, food bar, container of liquid of defined volume, or other forms described herein, packaged for one-time consumption or administration.
  • compositions described herein can provide several advantages, including but not limited to increased shelf stability, increased bioavailability, increased bioactivity, and delayed release.
  • the compositions described herein, when administered to a subject, can have various release profiles, half-lives, and metabolic characteristics.
  • the subject compositions can comprise a plurality of microcapsules, wherein an individual microcapsule in the plurality is characterized by exhibiting at least one of: (a) a sigmoidal release profile of the at least one cannabinoid compound; (b) a plasma half-life of the at least one cannabinoid compound greater than twice that of the at least one cannabinoid compound in non-encapsulated form; (c) a first pass metabolism of the at least one cannabinoid compound reduced by at least 50% compared to the at least one cannabinoid compound in non-encapsulated form; d) a rate of excretion of the at least one cannabinoid compound from a subject’s body reduced by at least 20% compared to the at least one cannabinoid compound in non-encapsulated form; or (e) a degradation rate at an ambient temperature of at least 20 °C of the at least one cannabinoid compound of less than about 50% of a degradation rate of the at least one cannabinoid compound
  • compositions described herein can have a shelf half-life of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 240, 270, 300, 330, or 360 days. In some cases, the compositions described herein can have a shelf half-life of at least about 1, 2, 3, 4, or 5 years.
  • compositions in microencapsulated form can be characterized by a cannabinoid degradation rate at an ambient temperature of at least 20 °C of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than the degradation rate of a non-encapsulated cannabinoid composition.
  • Cannabinoid compositions in microencapsulated form can be characterized by a plasma half-life in a subject of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60 70, 80, 90, or 100 times that of a non-encapsulated cannabinoid composition.
  • Plasma half-life of a composition can be determined experimentally by administering the composition to a subject, taking plasma samples from a subject at multiple time points, and measuring the concentration of the compound or compounds of interest in those plasma samples. The concentration of the compound or compounds of interest will reach a peak value in the plasma, then fall as the compound or compounds are metabolized, degraded, or cleared from the blood stream. The plasma half-life is the time for the plasma concentration value to be halved.
  • the cannabinoid release profile can be sigmoidal (e.g., having an ‘S’ shape curve, such as a logistic function).
  • the cannabinoid release profile can be non-sigmoidal.
  • the cannabinoid release profile can be linear.
  • the cannabinoid release profile can be non-linear.
  • the cannabinoid release profile can be instant release.
  • the cannabinoid release profile can be non-instant release.
  • the cannabinoid release profile can be delayed release.
  • the cannabinoid release profile can be constant or sustained release.
  • the cannabinoid release profile can be non-constant or nonsustained release.
  • Tablets can be formulated in sustained release format.
  • sustained release tablets There are various methods of making sustained release tablets; see, for example, U.S. Patent Publication No. 2006/0051416 and U.S. Patent Publication No. 2007/0065512, each of which is entirely incorporated herein by reference.
  • Examples of gradual-release tablets are provided in U.S. Patent No. 3,456,049, which is entirely incorporated herein by reference.
  • a slow- or sustained-release form may delay disintegration or absorption of the composition or one or more components thereof.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 1 hour of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 2 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 3 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 4 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 5 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 6 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 7 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a cannabinoid compound is released from a microcapsule within 8 hours of administration to a subject.
  • a release profile is the relationship between time and the amount of a compound released into a subject or the concentration of the compound within the subject (e.g., within the plasma). Release profiles can be measured in a similar manner to plasma half-life.
  • a composition can be administered to a subject, and samples (e.g., plasma samples or blood samples) can be taken from the subject at multiple time points. The concentration of the compound or compounds of interest can be measured in those samples, and a release profile can be plotted.
  • Compounds taken up into a subject via the gastrointestinal system can be transported to the liver before entering general circulation.
  • Compounds susceptible to metabolic degradation in the liver can have their activities substantially reduced by the first-pass metabolism through the liver.
  • Encapsulation (e.g., microencapsulation) of compounds can reduce first-pass metabolism of the compounds in the liver.
  • compositions in microencapsulated form can be characterized by a first pass cannabinoid metabolism in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of a non-encapsulated cannabinoid composition.
  • compositions in microencapsulated form can be characterized by a cannabinoid excretion rate from a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of a non-encapsulated cannabinoid composition.
  • compositions described herein when administered to a subject, can have improved bioavailability, bioactivity, or both.
  • Bioavailability is the fraction of an administered dosage of unchanged compound that reaches systemic circulation.
  • Cannabinoid compositions in microencapsulated form can be characterized by a bioavailability in a subject of at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0,
  • Cannabinoid compositions in microencapsulated form can be characterized by a bioavailability in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,%, 98%, 99%, or 100%.
  • Bioactivity is the activity exerted by the active ingredient or ingredients in a composition.
  • Cannabinoid compositions in microencapsulated form can be characterized by a bioactivity in a subject of at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4,
  • the subject compositions can comprise a plurality of microcapsules, wherein an individual microcapsule in the plurality is characterized by exhibiting at least one of (a) a sigmoidal release profile of the at least one non-cannabinoid therapeutic compound; (b) a plasma half-life of the at least one non-cannabinoid therapeutic compound greater than twice that of the at least one non-cannabinoid therapeutic compound in non-encapsulated form; (c) a first pass metabolism of the at least one non-cannabinoid therapeutic compound reduced by at least 50% compared to the at least one non-cannabinoid therapeutic compound in non-encapsulated form; d) a rate of excretion of the at least one non-cannabinoid therapeutic compound from a subject’s body reduced by at least 20% compared to the at least one non-cannabinoid therapeutic compound in non-encapsulated form; or (e) a degradation rate at an ambient temperature of at least 20 °C of the at least one non-cannabinoid
  • compositions described herein can have a shelf half-life of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 240, 270, 300, 330, or 360 days. In some cases, the compositions described herein can have a shelf half-life of at least about 1, 2, 3, 4, or 5 years.
  • compositions in microencapsulated form can be characterized by a non-cannabinoid therapeutic compound degradation rate at an ambient temperature of at least 20 °C of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than the degradation rate of a non-encapsulated non-cannabinoid therapeutic compound.
  • Non-cannabinoid therapeutic compounds in microencapsulated form can be characterized by a plasma half-life in a subject of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60 70, 80, 90, or 100 times that of nonencapsulated non-cannabinoid therapeutic compounds.
  • the non-cannabinoid therapeutic compound release profile can be sigmoidal (e.g., having an ‘S’ shape curve, such as a logistic function).
  • the non-cannabinoid therapeutic compound release profile can be non-sigmoidal.
  • the non-cannabinoid therapeutic compound release profile can be linear.
  • the non-cannabinoid therapeutic compound release profile can be non-linear.
  • the non-cannabinoid therapeutic compound release profile can be instant release.
  • the non-cannabinoid therapeutic compound release profile can be non-instant release.
  • the non- cannabinoid therapeutic compound release profile can be delayed release.
  • the non-cannabinoid therapeutic compound release profile can be constant or sustained release.
  • the non-cannabinoid therapeutic compound release profile can be non-constant or non-sustained release.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non- cannabinoid therapeutic compound is released from a microcapsule within 1 hour of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 2 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 3 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 4 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 5 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 6 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 7 hours of administration to a subject.
  • no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a non-cannabinoid therapeutic compound is released from a microcapsule within 8 hours of administration to a subject.
  • Encapsulation (e.g., microencapsulation) of non-cannabinoid therapeutic compounds can reduce first-pass metabolism of the non-cannabinoid therapeutic compounds in the liver.
  • Non-cannabinoid therapeutic compounds in microencapsulated form can be characterized by a first pass metabolism in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of non-encapsulated non-cannabinoid therapeutic compounds.
  • Non-cannabinoid therapeutic compounds in microencapsulated form can be characterized by an excretion rate from a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of non-encapsulated non- cannabinoid therapeutic compounds.
  • Non-cannabinoid therapeutic compounds in microencapsulated form can be characterized by a bioavailability in a subject of at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times that of non-encapsulated non-cannabinoid therapeutic compounds.
  • Non- cannabinoid therapeutic compounds in microencapsulated form can be characterized by a bioavailability in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,%, 98%, 99%, or 100%.
  • Non- cannabinoid therapeutic compounds in microencapsulated form can be characterized by a bioactivity in a subject of at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times that of non-encapsulated non-cannabinoid therapeutic compounds.
  • the subject composition e.g., a drug composition in a solid dosage form, such as a tablet or a pill
  • a drug composition in a solid dosage form can comprise a plurality of cannabinoid compounds and a plurality of non- cannabinoid
  • composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound can be characterized by a non-cannabinoid therapeutic compound degradation rate at an ambient temperature of at least 20 °C of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than the degradation rate of the cannabinoid compound.
  • the composition can be characterized by a non-cannabinoid therapeutic compound degradation rate at an ambient temperature of at least 20 °C of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% greater than a degradation rate of the cannabinoid compound.
  • degradation rates of a non-cannabinoid therapeutic compound and of a cannabinoid compound can be substantially the same.
  • the composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound can be characterized by a non-cannabinoid therapeutic compound plasma half-life in a subject of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60 70, 80, 90, or 100 times greater than that of a cannabinoid compound.
  • the composition can be characterized by a non-cannabinoid therapeutic compound plasma half-life in a subject of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6,
  • plasma half-lives of a non-cannabinoid therapeutic compound and of a cannabinoid compound in a subject can be substantially the same.
  • composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound can be characterized by a non-cannabinoid therapeutic compound release rate of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,
  • the composition can be characterized by a non-cannabinoid therapeutic compound release rate of at least about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60 70, 80, 90, or 100 times less than that of a cannabinoid compound.
  • release rates of a non-cannabinoid therapeutic compound and of a cannabinoid compound from the composition can be substantially the same.
  • composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound can be characterized by a first pass metabolism of the non-cannabinoid therapeutic compound in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% greater than that of a cannabinoid compound.
  • the composition can be characterized by a first pass metabolism of the non-cannabinoid therapeutic compound in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of a cannabinoid compound.
  • first pass metabolisms of the non-cannabinoid therapeutic compound and of the cannabinoid compound in a subject can be substantially the same.
  • composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound can be characterized by an excretion rate of the non-cannabinoid therapeutic compound in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% greater than that of a cannabinoid compound.
  • the composition can be characterized by an excretion rate of the non-cannabinoid therapeutic compound in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of a cannabinoid compound.
  • excretion rates of the non-cannabinoid therapeutic compound and of the cannabinoid compound in a subject can be substantially the same.
  • composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound
  • a bioavailability of the non-cannabinoid therapeutic compound in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% greater than that of a cannabinoid compound.
  • the composition can be characterized by a bioavailability of the non-cannabinoid therapeutic compound in a subject of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than that of a cannabinoid compound.
  • bioavailabilities of the non-cannabinoid therapeutic compound and of the cannabinoid compound in a subject can be substantially the same.
  • the composition as disclosed herein can comprise a first composition comprising a non-cannabinoid therapeutic compound and a second composition comprising a cannabinoid therapeutic compound.
  • the first composition and the second composition can be administered to a subject sequentially (e.g., one at a time) or simultaneously (e.g., all at once).
  • the first composition and the second composition can be administered to the subject via the same administration route (e.g., both orally) or different administration routes (e.g., one orally and the other intravenously).
  • the first composition and the second composition, as disclosed herein can be administered to a subject sequentially (e.g., via the same or different administration route(s)).
  • Administration of the first composition to the subject and administration of the second composition to the subject can be separated by at least about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, 24 hours, or more.
  • Administration of the first composition to the subject and administration of the second composition to the subject can be separated by at most about 24 hours, 20 hours, 16 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 50 minutes, 40 minutes, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, 1 minute, or less.
  • Subjects of the present disclosure can include humans and other animals, such as pets (e.g., dogs, cats, birds, small mammals, snakes) and livestock or farm animals (e.g., cows, pigs, horses, sheep, chickens).
  • Compositions of the present disclosure can be useful for veterinary applications.
  • compositions for various uses such as encapsulating compositions (e.g., therapeutics compositions).
  • a hemp oil composition comprising cannabinoids including cannabidiol. Additional essential oils are added to the composition. Alginate (e.g., sodium alginate) and quillaja tree extract are added to the composition. The composition is microencapsulated via a microfluidic nozzle device. Calcium chloride is used to cross-link the microcapsules. The microcapsules are packaged in a suspension, transported, and sold. Example 2 - Administration of Cannabinoid Composition to a Subject
  • a cannabinoid composition such as the microencapsulated cannabinoid composition described in Example 1, is administered to a subject suffering from a cannabinoid deficiency related condition.
  • the level of cannabinoids in the subject increases, and the condition is improved.
  • Hempseed oil is enriched in cannabidiol compounds by addition of hemp stalk and stem extract containing 10% to 40% cannabidiol compounds by weight.
  • the enriched hempseed oil is blended into coconut oil to produce a final composition of about 100 milligrams of cannabidiol compounds in 8 fluid ounces of coconut oil.
  • the coconut oil product is then used to produce consumer products such as moisturizers, lotions, cooking oils, smoothies, spreads, and other food products.
  • Hempseed oil is enriched in cannabidiolic acid by addition of hemp stalk and stem extract containing 10% to 40% cannabidiolic acid by weight.
  • the enriched hempseed oil is blended into coconut oil to produce a final composition of about 100 milligrams of cannabidiolic acid in 8 fluid ounces of coconut oil.
  • the coconut oil product is then used to produce consumer products such as moisturizers, lotions, cooking oils, smoothies, spreads, and other food products.
  • Hempseed oil is enriched in cannabidiol compounds by addition of hemp stalk and stem extract containing 10% to 40% cannabidiol compounds. Hempseed oil rich in cannabidiol compounds is then combined with cyclodextrin (e.g., certified organic cyclodextrin) to form a dry powder.
  • cyclodextrin e.g., certified organic cyclodextrin
  • the hemp oil powder is mixed with powdered cacao, cacao butter mix, sweeteners, and optionally superfood products such as reishi mushoom powder, chaga mushroom powder, maca, or he shou wu.
  • the mixture is packaged and sold as a chocolate beverage mix (e.g., hot chocolate mix).
  • a standardized supercritical carbon dioxide extract of hemp stalk and stem is extracted.
  • the extract e.g., a paste
  • the blend of hemp extract and hemp oil is prepared with a THC content below 0.3%, and with CBD content of about 10-40% by weight.
  • the hemp extract and hemp oil blend are further blended into coconut oil to provide about 100 mg of CBD per 8 ounce of coconut oil (about 423 milligrams per liter).
  • the coconut oil blend with CBD is packaged (e.g., in ajar) and sold to a consumer.
  • a cannabinoid and pregnenolone composition such as the microencapsulated cannabinoid composition described in Example 1 further comprising pregnenolone (e.g., 1-50 mg of pregnenolone), is administered to a subject suffering from cannabinoid intoxication or addiction.
  • pregnenolone e.g., 1-50 mg of pregnenolone
  • the subject is protected from CB1 receptor overactivation, and the condition is improved.
  • Formulations comprising quillaja extract e.g., Q Natural
  • hemp oil e.g., water
  • optionally sodium alginate were prepared using a microfluidic fluid processor (e.g., Microfluidizer from Microfluidics/IDEX Corporation).
  • a microfluidic fluid processor e.g., Microfluidizer from Microfluidics/IDEX Corporation.
  • Test 1 was prepared with 60 g of quillaja extract (e.g., Q Natural), 80 g of hemp oil, and 100 g of water, at an operating pressure of 30,000 psi in the microfluidic fluid processor.
  • Test 2 was prepared with 10 g of quillaja extract (e.g., Q Natural), 15 g of hemp oil, 198 g of water, and 2 g of sodium alginate, at an operating pressure of 30,000 psi in the microfluidic fluid processor.
  • quillaja extract e.g., Q Natural
  • particle size distribution was analyzed using a laser diffraction particle size analyzer (e.g., Horiba LA950). Optical microscope images were also taken.
  • a laser diffraction particle size analyzer e.g., Horiba LA950.
  • Test 1 and Test 2 Three passes each of Test 1 and Test 2 were conducted, and the tenth percentile (D10), fiftieth percentile (D50), and ninetieth percentile (D90) particle sizes are reported in Table 11. Particle sizes were also analyzed for an unprocessed solution (Test 1, Pass 0).
  • FIG. 1A shows a 400x magnification micrograph image of an unprocessed quillaja extract, hemp oil, and water composition (Test 1, Pass 0), with a 50 pm scale bar.
  • FIG. IB shows a lOOOx magnification micrograph image of an unprocessed quillaja extract, hemp oil, and water composition (Test 1, Pass 0), with a 50 pm scale bar.
  • FIG. 2A shows a 400x magnification micrograph image of a quillaja extract, hemp oil, and water composition (Test 1, Pass 1), with a 50 pm scale bar.
  • FIG. 2B shows a 400x magnification micrograph image of a quillaja extract, hemp oil, and water composition (Test 1, Pass 2), with a 50 pm scale bar.
  • FIG. 2C shows a lOOOx magnification micrograph image of a quillaja extract, hemp oil, and water composition (Test 1, Pass 2), with a 10 pm scale bar.
  • FIG. 2D shows a lOOOx magnification micrograph image of a quillaja extract, hemp oil, and water composition (Test 1, Pass 3), with a 10 pm scale bar.
  • FIG. 3A shows a lOOOx magnification micrograph image of a quillaja extract, hemp oil, water, and sodium alginate composition (Test 2, Pass 1), with a 10 pm scale bar.
  • FIG. 3B shows a lOOOx magnification micrograph image of a quillaja extract, hemp oil, water, and sodium alginate composition (Test 2, Pass 2), with a 10 pm scale bar.
  • FIG. 3C shows a lOOOx magnification micrograph image of a quillaja extract, hemp oil, water, and sodium alginate composition (Test 2, Pass 3), with a 10 pm scale bar.
  • a co-therapeutic composition such as the microencapsulated cannabinoid composition described in Example 1 further comprising a non-cannabinoid therapeutic compound is administered to a subject having a condition or is suspected of having such condition.
  • the subject is characterized by at least a partial remission of the condition.
  • the subject can have a cancer, and treatment with the co-therapeutic composition as disclosed herein can at least partially treat the cancer (e.g., decrease a size of a solid tumor of the subject).
  • the subject can have a CNS disease, and treatment with the co-therapeutic composition as disclosed herein can at least partially treat the CNS disease.
  • a co-therapeutic composition comprising a non-cannabinoid therapeutic compound and a cannabinoid compound (e.g., a solid composition as illustrated in FIGs. 5 and 6) is administered to a subject having a condition or is suspected of having such condition. Subsequent to the administration, the subject is characterized by at least a partial remission of the condition.
  • the subject can have a cancer, and treatment with the co-therapeutic composition as disclosed herein can at least partially treat the cancer (e.g., decrease a size of a solid tumor of the subject).
  • the subject can have a CNS disease, as disclosed herein, and treatment with the co-therapeutic composition as disclosed herein can at least partially treat the CNS disease.
  • Example 11 Co-administration of Cannabinoid with Doxorubicin
  • a co-therapeutic composition comprising a cannabinoid and doxorubicin is administered to a subject undergoing treatment of a cancer via the doxorubicin. Subsequent to the administration, the subject is characterized by at least a partial remission of the condition (e.g., a decrease in a size of a solid tumor of the subject). Subsequent to administration, the subject is further characterized by mitigation of cardiomyopathy via mitochondrial pathways and by activating, binding, or otherwise interacting with endocannabinoid receptors in the heart. Administration of the co-therapeutic composition comprising a cannabinoid and doxorubicin results in an improved patient outcome.
  • a co-therapeutic composition comprising a cannabinoid and ketamine is administered to a subject who exhibits symptoms of depression. Subsequent to the administration, the subject is characterized by increased antidepressant characteristics and reduced or eliminated psychostimulant effects as compared to an administration of ketamine individually. Subsequent to administration, the subject is characterized by diminished motor disturbance and support of fear extinction in neural networks.
  • a co-therapeutic composition comprising a cannabinoid and atorvastatin is administered to a subject undergoing treatment of high cholesterol via the atorvastatin. Subsequent to the administration, the subject is characterized by at least a partial reduction of cholesterol levels. Subsequent to administration, the subject is characterized by improved (e.g., decreased) cholesterol levels and neuroprotective effects from the administration of the co- therapeutic composition as compared to administration of atorvastatin individually.
  • Example 14 Co-administration of a Cannabinoid with Fluvastatin
  • a co-therapeutic composition comprising a cannabinoid and fluvastatin is administered to a subject undergoing treatment of high cholesterol via the fluvastatin. Subsequent to the administration, the subject is characterized by at least a partial reduction of cholesterol levels. Subsequent to administration, the subject is characterized by improved (e.g., decreased) cholesterol levels and neuroprotective effects from the administration of the co-therapeutic composition as compared to administration of the fluvastatin individually.
  • Example 15 Co-administration of a Cannabinoid and Dextromethorphan
  • a co-therapeutic composition comprising a cannabinoid and dextromethorphan is administered to a to a subject undergoing treatment for a cough via the dextromethorphan. Subsequent to the administration, the subject is characterized by at least a partial remission of the cough. Subsequent to administration, subject is characterized by decreased inflammation and enhanced liver protection as compared to administration of the dextromethorphan individually.
  • Example 16 Co-administration of a Cannabinoid with Ibuprofen
  • a co-therapeutic composition comprising a cannabinoid and ibuprofen is administered to a subject undergoing treatment of pain and inflammation via the ibuprofen. Subsequent to the administration, the subject is characterized by at least a partial remission of the pain and inflammation. Subsequent to administration, subject is characterized by decreased inflammation, decreased pain and enhanced liver protection as compared to administration of the ibuprofen individually.
  • Example 17 Co-administration of a Cannabinoid with Acetaminophen
  • a co-therapeutic composition comprising a cannabinoid and acetaminophen is administered to a subject undergoing treatment of pain and inflammation via the acetaminophen. Subsequent to the administration, the subject is characterized by at least a partial remission of the pain and inflammation. Subsequent to administration, subject is characterized by decreased inflammation, decreased pain, and enhanced liver protection as compared to administration of the acetaminophen individually.
  • Example 18 Co- Co-administration of a Cannabinoid with Naproxen
  • a co-therapeutic composition comprising a cannabinoid and naproxen is administered to a subject undergoing treatment of pain and inflammation via the naproxen. Subsequent to the administration, the subject is characterized by at least a partial remission of the pain and inflammation. Subsequent to administration, subject is characterized by decreased inflammation, decreased pain, and enhanced liver protection as compared to administration of the naproxen individually.
  • a co-therapeutic composition comprising a cannabinoid and diazepam is administered to a subject undergoing treatment of anxiety and depression via the diazepam. Subsequent to the administration, the subject is characterized by at least a partial remission of the anxiety and depression. Subsequent to administration, subject is characterized by synergistic anxiolytic effects, lower addiction potential, and protection of the subject’s liver and brain from the combination of cannabinoid and benzodiazepine as compared to administration of diazepam individually.
  • Example 20 Co-administration of a Cannabinoid and Alprazolam
  • a co-therapeutic composition comprising a cannabinoid and alprazolam is administered to a subject undergoing treatment of anxiety and depression via the alprazolam. Subsequent to the administration, the subject is characterized by at least a partial remission of the anxiety and depression. Subsequent to administration, subject is characterized by synergistic anxiolytic effects, lower addiction potential, and protection of the subject’s liver and brain from the combination of cannabinoid and benzodiazepine as compared to administration of alprazolam individually.
  • a co-therapeutic composition comprising a cannabinoid and clonazepam is administered to a subject undergoing treatment of anxiety and depression via the clonazepam. Subsequent to the administration, the subject is characterized by at least a partial remission of the anxiety and depression. Subsequent to administration, subject is characterized by synergistic anxiolytic effects, lower addiction potential, and protection of the subject’s liver and brain from the combination of cannabinoid and benzodiazepine as compared to administration of clonazepam individually. [00313] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La présente invention concerne des procédés et des systèmes pour former une composition co-thérapeutique. La composition co-thérapeutique peut comprendre un composé cannabinoïde et un composé thérapeutique non cannabinoïde. La composition co-thérapeutique peut comprendre une pluralité de gouttelettes stables en tant que partie d'une émulsion. La composition co-thérapeutique peut se présenter sous d'autres formes posologiques, telles que des formes posologiques solides (par exemple, des comprimés).
EP21901328.1A 2020-12-01 2021-11-30 Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes Pending EP4255405A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119862P 2020-12-01 2020-12-01
US202063119842P 2020-12-01 2020-12-01
PCT/US2021/061206 WO2022119840A1 (fr) 2020-12-01 2021-11-30 Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes

Publications (1)

Publication Number Publication Date
EP4255405A1 true EP4255405A1 (fr) 2023-10-11

Family

ID=81853512

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21901328.1A Pending EP4255405A1 (fr) 2020-12-01 2021-11-30 Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes

Country Status (4)

Country Link
US (1) US20240148760A1 (fr)
EP (1) EP4255405A1 (fr)
JP (1) JP2023552757A (fr)
WO (1) WO2022119840A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183618A1 (fr) * 2022-03-25 2023-09-28 Ojai Energetics Pbc Compositions psychédéliques et leurs procédés de formation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180303791A1 (en) * 2014-11-26 2018-10-25 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
GB2553139A (en) * 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10688191B2 (en) * 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CA3095970A1 (fr) * 2018-04-04 2019-10-10 Jay Pharma Inc. Combinaison d'un cannabinoide et d'un agent chimiotherapeutique pour le traitement du cancer du sein
US20220151982A1 (en) * 2019-03-28 2022-05-19 Scicann Therapeutics Inc. Cannabinoid compositions and use thereof

Also Published As

Publication number Publication date
WO2022119840A1 (fr) 2022-06-09
US20240148760A1 (en) 2024-05-09
JP2023552757A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
AU2021200019B2 (en) Microencapsulated cannabinoid compositions
US20240082174A1 (en) Methods and compositions for reducing oxidative stress
US20190046440A1 (en) Methods and systems for forming stable droplets
US20210330638A1 (en) Nano-penetrative cannabinoid oil blends and compositions and methods of formulation thereof
US20190247358A1 (en) Methods and compositions for potentiating stem cell therapies
US11318096B2 (en) Methods and systems for forming stable droplets
CN102405046A (zh) 表现出抗炎性质的药物组合物
EP4255405A1 (fr) Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes
US20230263810A1 (en) Systems, methods, and compositions for infections
US20240169856A1 (en) Cannabinoid compositions for virtual and augmented reality experiences
Høie et al. Lipid-lowering effect of 2 dosages of a soy protein supplement in hypercholesterolemia
Švajcer Interactions of Medicines with Dietic Supplements A
CN110167568A (zh) 基于加蓬野芒果提取物和双歧杆菌菌株的用于调节和减轻体重的组合物
KR20180105004A (ko) 한약 포장 방법
JP2007131643A (ja) アレルギー性疾患の症状を抑制・緩和するための薬剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)